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ABSTRACT 
SPECTRAL CHARACTERIZATION OF CYTOCHROMES P450 ACTIVE SITES 
AND CATALYTIC INTERMEDIATES 
 
 
Daniel Kaluka, B.Sc., M.S. 
 
Marquette University, 2012 
 
 
Cytochromes P450 (P450s) have been the subject of intense research for over six 
decades. Though it is widely accepted that a highly reactive Fe(IV)=O π-cation radical, or 
the so called compound I, facilitates the oxidation of relatively inert hydrocarbons, 
spectroscopic characterization of this putative intermediate has eluded detection under 
turnover conditions, presumably due to its very short lifetime. In this work, chemically 
inert substrates of P450s have been utilized in a new approach to capture and stabilize 
this transient intermediate and characterize it with resonance Raman (RR) spectroscopy, 
which is a well established tool for studying heme proteins. Specifically, 
perfluorodecanoic acid has been utilized as an inert surrogate substrate of a thermophilic 
cytochrome P450 designated CYP119 and RR and cryoradiolysis methods were 
employed to characterize the enzymatic intermediates under turnover conditions.  
 
In a separate project, a recent and more efficient approach for the isotopic labeling 
of the prosthetic group in heme proteins has been exploited to produce a 
13
C labeled 
analogue of the soluble bacterial cytochrome P450cam (P450cam). Briefly, the HU227 
strain of E. coli that lacks the δ-aminolevulinic acid (δ-ALA) synthase gene was 
employed in the heterologous expression of P450cam harboring a prosthetic group 
labeled with 
13
C at the Cm and Cα positions by growing cells in the presence of [5-
13C] δ-
ALA, which was synthesized in four steps from [2-
13
C] glycine. This system has been 
utilized as proof of principle for the strategy of defining active site structure in 
mammalian cytochromes P450 using NMR methods to furnish necessary experimental 
restrictions in docking routines, which are commonly employed in determining the 
relative affinities of drug candidates. Noting that few crystal structures of substrate bound 
complexes of drug metabolizing P450s exist, a truncated CYP2D6 gene has been 
designed following a recently published procedure and efforts were made to 
heterologously express a selectively 
13
C enriched analogue of this important drug 
metabolizing enzyme. 
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 Cytochromes P450 
 
 
Klingenberg (1958) is credited for the identification of the first cytochrome P450 
in rat liver michrosomes.
1
  A little later, in the early 1960s, Omura and Sato observed a 
characteristic Soret absorption maximum around 450 nm in the UV spectrum (Figure 
1.1.1) of a carbon monoxide saturated liver microsomes sample incubated with sodium 
diothionite
2
 These observations led to wide-ranging exploration of a class of heme 
proteins known as cytochromes P450 (P450s).   
 
Figure 1.1.1 The Fe (II)-CO difference spectra of liver michrosomes.  A,  Na2S2O4 
reduced microsomes; B, aerobic microsomes.
2
 
 
 
These  single polypeptide chain heme proteins of between 400-500 amino acid 
residues are found in all five biological kingdoms.
3,4 
The name heme proteins is derived 
from the characteristic iron-porphyrin prosthetic group or the so-called heme, in the 
2 
 
 
active site of these proteins. Natural occurring heme types include heme a, b, c and d 
(Figure 1.1.2)
5,6
  Heme b bearing proteins have been the subject of intensive structure 
function studies. The prosthetic group’s attachment to the surrounding protein matrix 
accounts for the apparent versatility and ubiquitous nature of these metalloproteins.
7 
The 
heme group in P450s is covalently linked to the protein via an Fe‒S bond (provided by a 
cysteinic sulfur acting as the fifth ligand) bond at the proximal side of the prosthetic 
group, whereas most other heme proteins such as, hemoglobin and myoglobin exhibit a 
histidyl imidazole linkage.
8,9
Additional covalent attachments with the heme peripheral 
groups have been documented for lactoperoxidases and myeloperoxidases.
10,11
  
3 
 
 
 
Figure 1.1.2 The structures (and numbering) of the natural occurring heme groups (a-
d)
5,6
 
The heightened research focus on this class of heme proteins stems primarily from 
their role as biological catalysts. P450s have been reported to bind and cleave molecular 
oxygen generating a potent intermediate capable of hydroxylating even relatively inert 
hydrocarbon substrates.
12,13
This interesting chemistry has been observed in a variety of 
important biological processes that include biosynthesis of lipids, steroids, antibiotics and 
the degradation of xenobiotics (Figure 1.1.3).
7
 It is obviously of immense practical 
interest to gain a better understanding of this apparently ubiquitous chemistry exhibited 
by these important biological catalysts.  
4 
 
 
 
 
 
Figure 1.1.3 The many roles of P450cam in metabolism
7 
 
1.1.1 The P450s catalytic cycle 
 
The advancement in genomic studies has seen the unraveling of greater than 3000 
genes encoding P450s in plant, fungi, bacterial and mammalian sources.
3,4
 Among these, 
a soluble heme protein known as cytochrome P450cam (P450cam) from the bacteria 
Pseudomonas putida has been well studied. 
14–16
 Researchers attempting to better 
understand the chemistry of P450s have taken advantage of this probably best 
characterized prototype of the P450 superfamily. Crystal structure studies have detected 
the presence of a hydrogen bonded water cluster in the substrate-free enzyme’s distal 
5 
 
 
pocket.
15,17–19
 In the resting state, one of the water molecules is bound to the iron-
porphyrin complex giving a hexa-coordinated low spin ferric form of the enzyme (Figure 
1.1.4).
20
 It has now been well documented that binding of camphor (or its analogues) or 
redox partners by P450cam induce structural changes with important functional 
significance.
21,22
 In the catalytic cycle shown in Figure 1.1.4, binding of substrate to a 
relatively planar hexa-coordinated iron-porphyrin complex induces a spin state change to 
a 5-coordinate high spin (5CHS) form of the enzyme (2). In P450cam, it has been shown 
that binding of substrate and its redox partner, putidaredoxin,  modulates the heme 
equilibrium redox potential (from -303 mV to -173 mV)  signifying susceptibility to 
reduction of the 5CHS P450cam  (Figure 1.1.5).
21,23–25
 
 
Delivery of one electron 
equivalent, by putidaredoxin, is followed by binding of oxygen, giving rise to a dioxygen 
adduct of P450cam (4). Spectroscopic characterization of this intermediate in P450cam is 
well documented.
26–29
 Addition of a second electron by the redox partner produces the 
heme-bound peroxo intermediate (5a). This intermediate (5a) and its protonated form, the 
ferric hydroperoxo species (5b) have recently been characterized by electronic 
absorption, EPR and resonance Raman spectroscopic methods.
20,28,30
 Proton assisted 
scission of the dioxygen bond of the hydroperoxo species results in the formation of the 
transient reactive intermediate of P450s (6), the equivalent of the so-called compound I of 
peroxidases. This elusive intermediate has eluded spectroscopic characterization under 
turnover conditions.  
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Figure 1.1.4 The catalytic cycle of P450cam
20 
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Figure 1.1.5 The structures of all the three components of P450cam
23
 
 
1.1.2 Heme iron interactions with diatomic ligands 
 
Important structural data have been obtained by taking advantage of the fact that 
these heme proteins are capable of binding exogenous diatomic ligands such as NO, CO 
and CN
-
 in addition to the endogenous O2 discussed above for P450cam. The binding of 
these ligands to the iron-porphyrin complex through σ- and π-interactions gives rise to 
linear or bent geometries (Figure 1.1.6).
31–33
 The dispositions of these ligands in the 
active site, which can be spectroscopically interrogated, have been used as probes 
reporting on active site architecture that can influence important functional properties of 
heme proteins. Two σ type interactions are possible: one in which the metal dz2 orbital 
overlaps with the ligand lone pair and another involving the metal dz
2 and the ligand π* 
orbitals. The strength of the metal-ligand bond depends on the extent of orbital overlap, 
thus weak bonding exists between metal and a ligand exhibiting a high energy π* orbital. 
 
8 
 
 
For example, the strength of σ-bonding interaction increases from CO, NO to O2 as the 
π*-orbital energy decreases. In π-interactions, back donation of electrons from the filled 
metal dxy and dyz orbitals to the vacant ligand π* orbital results in the strengthening of the 
M-X bond and weakening of the X-Y bond. Although the nature of these interactions 
defines the theoretical geometry of the M-X-Y linkage, distortions are to be expected in 
the protein matrix due to the interactions between the ligand and amino acid residues in 
close proximity.
6
 
 
Figure 1.1.6  Schematic representation of σ- and π-bonding in heme proteins.8 
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1.1.3 Optical properties of cytochromes P450 
 
 
The optical properties exhibited by cytochromes P450 enzymes allows for the use 
of a variety of spectroscopic tools in the quest for an understanding of the inherent 
chemistry observed in these proteins. The heme group in P450s gives rise to strong π-π* 
electronic transitions in the visible region due to the extended nature of the porphyrin 
aromatic system. The spectral features of a typical metalloporphyrin, ferrocytochrome c, 
are shown in the figure below (Figure 1.1.7).
6
 The characteristic bands include an intense 
band at around 400 nm, the so-called B or Soret band and a pair of weak bands near 520 
nm and 550 nm, referred to as Q0(or α) and Q1(or β) bands, respectively. The 
unsubstituted tetrapyrrole macrocycle has D4h symmetry exhibiting two degenerate 
lowest unoccupied π* orbitals (LUMO) of eg symmetry and two highest filled π orbitals 
(HOMO) of a1g and a2u symmetries. The energies of the two HOMOs are nearly the same 
allowing strong configuration interaction of the possible transitions, A1u  Eg and A2u  
Eg; addition of the transition dipoles gives rise to the strong Soret band whereas they 
nearly cancel out for the Q0 transition. The apparent increase in intensity observed for the 
Q1 transition is a result of vibronic mixing with the B transition.
6,34  
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Figure 1.1.7 Absorption spectrum of Cytochrome c and the structure of a 
metalloporphyrin with D4h symmetry
6
 
 
The 6 coordinate low spin (6CLS) substrate-free P450cam exhibits a Soret 
absorption maximum at 418 nm, which shifts down to 391 nm upon binding of substrate. 
The downshift is associated with spin state change from the 6CLS to 5CHS (Figure 
1.1.8).
35
 Cytochrome P420cam, the inactive form of P450cam, has a Soret band at 420 
nm, which is presumably the reduced carbonmonoxy form (reduced P420-CO form) 
exhibiting histidyl ligation. The proximal thiolate fifth ligand is thought to be replaced by 
a histidyl residue resulting in a lack of enzymatic activity giving evidence of the critical 
role played by the axial ligand in heterolytic cleavage of the dioxygen species trans to 
it.
36 
However, later studies have suggested that the P420 form may be reasonably 
described as possessing a protonated thiol axial ligand.
37
 
11 
 
 
 
Figure 1.1.8 Absorption spectra of different forms of P450cam in the Soret region; 
Fe(III) substrate free (m
o
), Fe(III) substrate bound (m
os
), Fe(II) substrate bound (m
rs
), 
Fe(II)-CO substrate bound     
  ).
35
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1.2 Raman Spectroscopy 
 
The Raman Effect phenomenon results when light from a laser source impinges 
upon a molecule and interacts with the electron cloud of the bonds making up the 
molecule. Interaction with the incident radiation may result in vibrational excitation of 
the molecule from its electronic ground state, ν0 and/or a less populated vibrational 
excited state, ν1 to a virtual energy state. Stokes Raman scattering, or the so-called 
spontaneous Raman Effect, is generated following vibrational relaxation whereby the 
energy of the scattered light is less than the incident radiation. Vibrational relaxation 
from a virtual excited to the electronic ground state (ν0) results in Rayleigh or elastic 
scattering; that is, the energy of the incident photon is the same as that of the emitted 
photon. Excitation of the molecule already in a vibrational excited state (ν1) followed by 
relaxation to a lower vibrational level (ν0) produces anti-Stokes Raman scattering, as 
shown in the figure below (Figure 1.2.1). As expected and in accordance with the 
Maxwell-Boltzmann distribution law, Stokes Raman scattering exhibits stronger 
intensities than anti-Stokes since the vibrational excited levels (ν1) are far much less 
populated than the ground state (ν0); i.e., the intensities of the anti-Stokes Raman lines 
decreases rapidly as the vibrational frequencies increase. Consequently, conventional 
Raman spectroscopy considers the Stokes lines in which the scattered light intensities are 
reported as a function of the frequency difference from the monochromatic source or 
more commonly as Raman shifts. Key to the exhibition of the Raman Effect is the 
polarizability of the molecule with respect to the vibrational coordinate. The degree of 
polarizability is reflected in the Raman scattering intensity, whereas Raman shifts report 
on the molecular vibrational levels. 
13 
 
 
 
Figure 1.2.1 Schematic representation of the Raman Effect 
  
1.2.1 Resonance Raman Spectroscopy 
 
Resonance Raman spectroscopy involves measuring enhanced Stokes lines as the 
excitation frequency approaches the energy of the electronic transition of the target 
chromophore. The technique is ideally suited for studying complex biological molecules 
like heme proteins inasmuch as it permits active site interrogation owing to its ability to 
selectively enhance vibrational modes of the chromophoric heme prosthetic group.
38
 This 
powerful spectroscopic tool has long been established as an exquisite probe of active site 
structure for a wide range of heme proteins and enzymes.
6,38,39 
The technique offers a 
major advantage over IR spectroscopy in that there is no interference from water making 
it a method of choice for studying vibrational properties of proteins, samples of which are 
typically in aqueous buffers.  The vibrational modes of the prosthetic heme group buried 
in the active site of these large biological polymers are selectively enhanced by exploiting 
laser (excitation) lines which are in or near resonance with the Soret or Q bands 
electronic transitions.  
14 
 
 
Isotopic labeling (
15
N, 
13
C and 
2
H) of high symmetry model compounds, such as 
metal complexes of tetraphenylporphyrin (H2TPP), octaethylporphyrin (H2OEP), 
etioporphyrins (H2(EtioI)) and (H2(EtioIII), has been used to unambiguously assign heme 
core vibrational modes.
40,41
 If each peripheral substituent of the iron protopophyrin IX 
complex is considered as a point mass, the heme has D4h symmetry giving a total of 37 
atoms and 105 vibrational modes. The modes consist of 71 in-plane (ip) modes (2N-3) 
and 34 out-of-plane (oop) modes (N-3) and are classified as follows: 
ip = 9A1g + 8A2g + 9B1g + 9B2g + 18Eu 
oop =3A1u + 6A2u + 5B1u + 4B2u + 8Eg 
Of the 71 in-plane vibrational modes 35 (g symmetry) are Raman active whereas 18 (Eu) 
are infrared active. These modes have been assigned for Ni
2+
 complexes of OEP, 
porphine and TPP using isotopic substitution and normal coordinate analysis and are 
given in the table below (Table 1.2.1).
6,42–45
  
Most applications have focused on the so-called marker bands in the high 
frequency region, which effectively document oxidation and spin states of the central 
iron, in addition to providing a reliable indicator of heme core size.
6,40  
The oxidation 
marker band (4), occurring at ~1360 cm
-1
 in Fe(II) and ~1375 cm
-1
 in Fe(III) species, is 
ascribable to the pyrrole ring symmetric stretch, which is very sensitive to the oxidation 
state of the central iron. The so-called spin state marker bands (ν2, ν3 and ν10) report on 
the core size and spin state of the iron center (Table 1.2.1). In recent years it has become 
increasingly apparent that low frequency modes (100-600 cm
-1
) in the RR spectra of 
heme proteins are quite sensitive to active site structure changes that can induce out-of-
15 
 
 
plane distortions of the macrocycle or alter the orientation of the heme peripheral 
substituents
46–55
  (see Figure 1.1.1 for protoheme labeling scheme). 
Table 1.2.1 Assignment and frequencies of in-plane vibrational modes of some nickel 
porphyrins complexes
6
  
 
 
Symmetry νi Description NiOEP NiP NiTPP
A1g ν1 ν(Cm-X) [3041] [3042] 1235
ν2 ν(CβCβ) 1602 1575 1572
ν3 ν(Cα-Cm)sym 1520 1459 1470
ν4 ν(Pyr half ring)sym 1383 1376 1374
ν5 ν(Cβ-Y)sym 1138 [3097] [3097]
ν6 ν(Pyr breathing) 804 995 1004
ν7 δ(Pyr def)sym 674 731 889
ν8 ν(Ni-N) 360/343 369 402
ν9 δ(Cβ-Y)sym 263/274 1066 1079
B1g ν10 ν(Cα-Cm)asym 1655 1650 1594
ν11 ν(CβCβ) 1577 1505 1504
ν12 ν(Pyr half ring)sym 1331 1319 1302
ν13 δ(Cm-X) 1220 1185 238
ν14 ν(Cβ-Y)sym 1131 [3097] [3097]
ν15 ν(Pyr breathing) 751 1003 1009
ν16 δ(Pyr def)sym 746 730 846
ν17 δ(Cb-Y)sym 305 1060 784
ν18 ν(Ni-N) 168 237 277
A2g ν19 ν(Cα-Cm)asym 1603 1611 1550
ν20 ν(Pyr quarter ring) 1394 1354 1341
ν21 δ(Cm-X) 1307 1139 [257]
ν22 ν(Pyr half ring)asym 1121 1005 1016
ν23 ν(Cβ-Y)asym 1058 [3087] [3087]
ν24 δ(Pyr def)asym 597 806 828
ν25 δ(Pyr rot.) 551 429 560
ν26 δ(Cβ-Y)asym [243] 1317 1230
B2g ν27 ν(Cm-X) [3041] [3041] 1269
ν28 ν(Cα-Cm)sym 1483 1504 [1481]
ν29 ν(Pyr quarter ring 1407 1368 1377
ν30 ν(Pyr half ring)asym 1160 1003 1004
ν31 ν(Cβ-Y)asym 1015 [3088] [3087]
ν32 δ(Pyr def)asym 938 819 869
ν33 δ(Pyr rot.) 493 435 450
ν34 δ(Cβ-Y)asym 197 1193 1191
ν35 δ(Pyr tranl.) 144 197 109
Eu ν36 ν(Cm-X) [3040] [3042] [1254]
ν37 ν(Cα-Cm)asym [1637] 1624 [1586]
ν38 ν(CβCβ) 1604 1547 [1552]
ν39 ν(Cα-Cm)sym 1501 1462 [1473]
ν40 ν(Pyr quarter ring) 1396 1385 [1403]
ν41 ν(Pyr half ring)sym [1346] 1319 [1331]
ν42 δ(Cm-X) 1231 1150 [233]
ν43 ν(Cβ-Y)sym 1153 [3097] [3097]
ν44 ν(Pyr half ring)asym 1133 1033 [1003]
ν45 ν(Cβ-Y)asym 996 [3087] [3100]
ν46 δ(Pyr)asym 927 806 [864]
ν47 ν(Pyr breathing) 766 995 [1023]
ν48 δ(Pyr)sym 605 745 [895]
ν49 δ(Pyr rot.) 544 366 [512]
ν50 ν(Ni-N) [358] 420 [436]
ν51 δ(Cb-Y)asym 328 1064 [1093]
ν52 δ(Cβ-Y)sym 263 1250 [1213]
ν53 δ(Pyr transl) 212 282 [306]
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1.2.2 RR spectroscopy of cytochromes P450 
 
 
RR spectroscopy has unraveled a wealth of information on the structure and 
function of cytochrome P450cam, which has since been considered as a prototype for the 
cytochrome P450 gene family.
35,56–58
  The heme vibrational modes of the substrate-free 
and substrate bound forms of both the ferric and ferrous states of P450cam have been 
assigned (Table 1.2.2).
36 
In the high frequency region the oxidation state marker band (ν4) 
occurring at 1374 cm
-1
 for the 6CLS substrate free P450cam (m
o
) and 1370 cm
-1
 for the 
5CHS camphor bound P450cam (m
os
) are characteristically shifted to lower frequency as 
compared to other heme proteins (Figure 1.2.2, A). This was attributed to the presence of 
a strong electronic donating axial fifth ligand of the iron center, which has since been 
documented to be the mercaptide of cysteine.
39,59
 RR studies of isotopically labeled 
P450cam confirmed the presence of the Fe-S bond, exhibiting a (Fe−S) that occurs at 
351 cm
-1
 that is observed only for the (5CHS) substrate bound form (Figure 1.2.3).
56 
The 
6CLS substrate free P450cam spin state marker bands occurring at 1503 and 1638 cm
-1
 
down shift to 1488 and 1624 cm
-1
, respectively, upon binding of substrate, indicating spin 
state conversion to the 5CHS camphor bound P450cam (Figure 1.2.2, B).
60
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Table 1.2.2 P450cam heme modes assignment
36
 
 
Sample ν8 ν35 δCbCαCβ ν7 ν15 ν4 ν3 ν2 ν10 
m
o
 347 379 424 678 753 1373 1503 1584 1635 
m
os
 347 379 424 678 755 1372 1488 1570 1623 
m
r
 345 378 418 674 747 1345 1468 1563 1601 
m
rs
 345 378 415 674 747 1345 1466 1564 1601 
m
r
co 352 379 423   1371 1497 1588  
m
rs
co      1372 1498 1583 1626 
 
 
 
Figure 1.2.2 Resonance Raman spectra of ferric P450cam and its complex with oxidized 
putidaredoxin in the (A) high frequency region and (B) ν3 spin state marker regions
60
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Figure 1.2.3 Resonance Raman spectrum of ferric camphor-bound P450cam is shown in 
the lower curve. The insert on the right is the absorption spectrum indicating the 
excitation line and on the left are the difference spectra in the region of the 351 cm
-1
 
Raman mode
56
 
 
 
The RR spectrum of the reduced 5CHS substrate bound form of P450cam (m
rs
) 
exhibits anomalously low frequency ν4 (1346 cm
-1) and ν3 (1466 cm
-1
) modes compared 
to other ferrous heme proteins due to the strong π donation by the axially coordinated 
cysteine thiolate.
39
 In the P450cam catalytic cycle (Figure 1.1.4), reduction of the 
substrate bound P450cam is followed by oxygen binding resulting in the formation of a 
relatively unstable dioxygen adduct of P450cam (4). RR evidence of the formation of the 
dioxygen adduct were provided by Champion and coworkers,
61
 who observed the 
strongly enhanced (O−O) mode near 1140 cm-1, and by Hu et al,62 who observed the 
ν(Fe−O2) at ~540 cm
-1
.  Interestingly, Hu and coworkers also showed that two ν(O−O) 
are seen at 1139 cm
-1
 and 1147 cm
-1
 for the dioxygen adduct of the 
P450cam/adamantanone complex. The detection of the two ν(O−O) modes was attributed 
to the existence of two distinct substrate configurations at the binding site, this proposal 
19 
 
 
being consistent with X-ray crystallography results reported for the adamantanone-bound 
P450cam (Figure 1.2.4).
63
 
 
 
Figure 1.2.4 The low (left traces) and high (right traces) frequency spectra of the 
dioxygen adduct of adamntanone bound P450cam; trace A, 
16
O2; trace B, 
18
O2; trace C, 
difference spectrum A-B
62
 
 
 
 
More recently, cryogenic RR detection of the ν(16O−16O) mode occurring at 1140 
cm
-1
 and the corresponding ν(18O−18O) at 1074 cm-1 of the oxyferrous complex of the 
D251N mutant of P450cam has been reported (Figure 1.2.5).
20
  In the natural catalytic 
cycle, the overall rate limiting step in the hydroxylation of camphor is the reduction of 
the dioxygen adduct. This step is facilitated by the redox partner, putidaredoxin, which 
delivers a second electron to the dioxygen-bound ferrous state of P450cam yielding the 
ferric peroxo intermediate. These species do not accumulate to large enough population 
due to their rapid decay under turnover conditions, complicating spectral investigation 
20 
 
 
efforts.  A cryoradiolytic reduction method, which utilizes -rays to generate free 
electrons from frozen aqueous buffer containing glycerol, was developed by Symons
64
 
and further refined by Hoffman and Davydov, and coworkers
30,65–68
 and has been 
employed in the reduction of cryotrapped oxyferrous complex of P450cam. An EPR and 
ENDOR study of cryoradiolytically reduced dioxygen adducts of wild type and D251N 
mutant P450cam reported generation of the hydroperoxo and peroxo intermediates 
respectively.
30,65
 The peroxo intermediate in the wild type protein, eluded detection 
following irradiation owing to the active site structure, which facilitates delivery of the 
first proton of catalysis even at 77 K yielding the hydroperoxo intermediate instead.
30,65
  
On the other hand, in the D251N mutant P450cam, proton delivery to the active site is 
hindered. This gave a distinct EPR signature characteristic of the peroxo intermediate, 
which, upon annealing, converted to a spectrum consistent with the hydroperoxo 
intermediate.
30,65
 In another study, utilization of this mutant permitted RR detection of 
two isotopically sensitive modes occurring at 553 cm
-1
 and 792 cm
-1
 exhibiting shifts of 
27 and 38 cm
-1
 respectively.
20
 These have been reasonably assigned to the (Fe−O) and 
(O−O) of the peroxo intermediate of the cyroreduced oxyD251N samples since no H/D 
shifts were observed at 77 K (Figure 1.2.6). Proton delivery to the active site in this 
mutant was cleverly achieved by annealing the peroxo species to ~ 180 K; resulting in the 
hydroperoxo intermediate characterized by RR spectroscopy.
20
 As expected H/D shifts in 
the RR spectra of annealed samples of  irradiated oxyD251N were observed for the 
modes occurring at 564 cm
-1
 and 774 cm
-1
 consistent with the (Fe−O) and (O−O) 
stretching frequencies of the hydroperoxo intermediate of the D251 mutant P450cam 
(Figure 1.2.7).
20
 However, the highly reactive ferryl species, the equivalent of the so-
21 
 
 
called compound I of peroxidases, presumably formed by cleavage of the O−O bond, has 
eluded spectroscopic characterization under turnover conditions.  
 
 
 
Figure 1.2.5 The high frequency RR spectra of the dioxygen complex of the D251N 
mutant of P450cam. Inset shows the difference spectra in the low frequency (Fe−O) 
region
20
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Figure 1.2.6 RR spectra of irradiated dioxygen adducts of P450 D251N in H2O buffer, 
spectra A (
16
O2) and B (
18
O2), and in D2O buffer, spectra C(
16
O2) and D (
18
O2). The two 
bottom traces shows the difference spectra of 
16
O2-
18
O2 in H2O and D2O buffers
20
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Figure 1.2.7 RR spectra of irradiated and annealed (at 185 K) samples of oxyD251N in 
H2O buffer, spectra A (
16
O2) and B (
18
O2), and in D2O buffer, spectra C (
16
O2) and D 
(
18
O2). The two bottom traces show the difference spectra of 
16
O2-
18
O2 in H2O and D2O 
buffers
20
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1.3 NMR spectroscopy of heme proteins 
 
 
Nuclear magnetic resonance (NMR) spectroscopy of heme proteins dates back to 
1962 when the first 
1
H NMR of a paramagnetic cytochrome c was obtained.
69,70
 
Researchers have since then utilized NMR methods unveiling a wealth of useful 
structural and functional properties of heme proteins in solution, which is an obviously 
important addition to structural determination, a realm previously dominated by x-ray 
crystallography. Paramagnetic heme proteins induce enhanced relaxation of surrounding 
NMR detectable signals due to electron-nuclear hyperfine interaction as a function of 
nuclei distances from the heme iron.
71
 As a consequence the prosthetic group chemical 
shifts experience isotropic shifts and are well resolved outside the diamagnetic protein 
envelope. These paramagnetic shifts are composed of scalar (contact) and dipolar 
(through space) contributions of the unpaired electron onto surrounding nuclei.
71
 The 
observation of well resolved heme proton signals has allowed for the development of 
NMR methods employed in the investigation of structure and dynamics in paramagnetic 
proteins. One obvious drawback of these extremely short relaxation times of 
paramagnetic signals is their inherent large line widths as compared to corresponding 
isostructural diamagnetic molecules. This finding complicates efforts to utilize multi-
dimensional NMR experiments in structural studies due to loss of magnetization. 
Methods have, however, been developed to enhance the paramagnetic signals in heme 
proteins and allowed for the assignment of heme methyl resonances. Specifically, the so-
called paramagnetic signals enhancement (PASE) method was applied in 1D and 2D 
experiments of high and low spin ferric complexes of the bacterial P450cam leading to 
the assignment of heme 
1
H methyl resonances (Table 1.3.1).
72
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Table 1.3.1
 1
H NMR assignments of the heme methyl resonances for ferric high and low 
spin P450cam
72
 
 
 
 
Binding of exogenous high field ligands such as the cyanide ion shifts the heme iron spin 
state from high to low spin, which exhibits slightly reduced line widths and affords some 
increased stability of the protein as in the case of P450cam allowing for high temperature 
experiments.
72
 The assignment of heme proton resonances of the cyano complex of 
P450cam has been reported previously (Figure 1.3.1).
73
 
 
 
Figure 1.3.1 1H NMR of camphor-free (B), camphor bound (B) cyanoP450cam and 
ferric high spin camphor bound P450cam. Insert table shows assignment of heme proton 
resonances.
73
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As mentioned previously, ligands in the distal pocket of the heme proteins have been 
used as spectroscopic probes. Recently, Sem and coworkers have demonstrated the use of 
13
C-methyl isocyanide bound to the heme iron of both bacterial and mammalian P450s as 
a potential NMR probe for the elucidation of structural and electronic changes in P450 
active sites.
74
 
13
C NMR (an established powerful ally of 
1
H NMR) application in the study of 
heme proteins has previously lagged behind mainly due to the low sensitivity and natural 
abundance of the 
13
C nuclei, but has recently gained a lot of interest due to the impressive 
development of high field NMR instruments and methods for judiciously enriching 
specific carbon atoms of the heme prosthetic group. An understanding of the heme 
biosynthetic pathway coupled with the developments in recombinant DNA technology 
has allowed for the production of isotopically enriched prosthetic groups (Figure 1.3.2). 
13
C labeled heme groups have been produced by supplementing bacterial cultures with 
labeled -aminolevulinic acid (ALA), which is the first committed precursor in the heme 
biosynthetic pathway (Figure 1.3.3).
75–77
 
27 
 
 
 
Figure 1.3.2 Biosynthesis of 13C enriched (black dots) protoporphyrin IX75 
 
Recently, an E.coli strain, the so-called HU227, lacking the δ-aminolevulinic acid (δ-
ALA) synthase gene has been exploited for the heterologous expression of P450s 
harboring prosthetic groups, which are close to 100% 
13
C labeled at the Cm and Cα 
positions (Figure 1.3.3, B), by growing  the cells in the presence of [5-
13C] δ-
aminolevulinic acid (ALA).
78
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Figure 1.3.3 Enrichment of the heme group at various positions using isotopically 
labeled -ALA75 
 
 
These developments have allowed the utilization of 
13
C NMR as a useful tool in the 
elucidation of important structural information in paramagnetic heme proteins.
13
C 
chemical shifts in enriched samples of ferric high spin myoglobin have been 
demonstrated to report on the coordination state of the heme protein.
79
  Selective 
13
C 
enrichment of the bacterial cytochrome c552 heme cofactor was achieved by expressing 
the cells in minimal media supplemented with [5-
13
C] -ALA.80 The observation of meso 
signals, which otherwise may prove to be a challenge owing to their being buried in the 
protein diamagnetic region, was made possible by 
13
C enrichment allowing for the 
application of a proton-detected single-bond correlation experiment commonly known as 
1
H-
13
C heteronuclear multiple-quantum correlation (HMQC). This correlation of coupled 
heteronuclear spins across a single bond provides connectivities between proton and 
carbon nuclei of a given compound. The 2D spectrum shown in Figure 1.3.4
80
, exhibits 
crosspeaks correlated to attached nuclei at the four meso positions.  
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Figure 1.3.4 
1
H-
13
C HMQC spectra of oxidized wild type (WT) and mutant AF7 [5-
13
C] 
-ALA Hydrogenobacter thermophilus (Ht) cytochrome c552
80
 
 
 
The assignment of meso 
1
H and 
13
C resonances was achieved by 
1
H-
13
C HMQC and 
1
H-
1
H nuclear Overhauser effect (NOE) experiments. NOE experiments involve the 
magnetic interaction of nuclei spins through space or the so-called dipolar coupling in 
contrast to scalar coupling in the HMQC technique. Thus the technique can be used in 3D 
structural investigations establishing spatial proximity between protons. These techniques 
were exploited to demonstrate the potential of the heme meso 
1
H and 
13
C resonances as 
NMR probes for heme ruffling OOP deformations.
80
  The ability to selectively enrich the 
heme core carbon opens up the possibility of utilizing NOE experiments in mapping the 
active site architecture. This finding is potentially ground breaking in as much as it 
allows for active site interrogation of proteins in solution, including drug metabolizing 
P450s, for which few crystal structures with substrates exists.  
 Computational docking is routinely employed in the prediction of binding 
affinities of potential substrates and inhibitors of drug metabolizing P450s. Essentially a 
lowest energy P450-substrate/inhibitor complex is obtained after optmization, which 
30 
 
 
involves calculatation of energies of interaction between protein and ligand. 
Unfortunately, efficient and accurate prediction of protein-ligand interactions by these 
computational methods is compromised by the inherent flexibility of drug metabolism 
P450s binding sites, such as in CYP2D6, which metabolizes 20-30% of all drugs. NOE 
experiments on P450s bearing heme groups or active site residues with judiciously placed 
isotopic labels could be exploited in defining solution phase active site structure. 
Specifically, NOE measurements of interatomic distances between reference points on 
the heme group and active side residues will provide a map of the substrate-free active 
site. Employing several substrates in the pocket and obtaining NOE derived distances 
between reference points (
13
C- enriched heme core carbons and /or 
13
C-labeled amino 
acid residues in the active site) and substrate protons will provide information on the 
flexibility/rigidity of P450s active site. Inasmuch as mapping of these flexible active sites 
is computationally demanding, employing expereimentally derived interatomic distances 
in docking routines would speed the process and potentially lead to more accurate 
pridictions of substrate or inhibitor interactions with the drug  metabolizing P450.  
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1.4 Specific issues to be addressed in this work 
 
1.4.1 Utilization of chemically inert substrates to stabilize compound I intermediates 
of P450s 
 
 
In the widely accepted natural catalytic cycle, the highly reactive Fe(IV)=O 
porphyrin π-cation (6) radical or the so called compound I intermediate, which results 
from a proton assisted scission of the O-O bond has eluded spectroscopic 
characterization, presumably owing to its inherently short life time and has recently 
earned the “mystery” title.81 In recent years several experimental approaches have been 
used to artificially produce compound I and investigate its electronic structure and 
reaction kinetics.
82–91
 The application of spectroscopic methods in the characterization of 
these species has been reviewed recently.
92,93
 An artificially produced compound I form 
of CYP119 has been reported to be an Fe(IV)=O-porphryin π-cation radical, exhibiting a 
ferryl iron spin (S=1) that is antiferromagnetically coupled to the S` = ½  of the porphyrin 
radical, giving a total spin of ½, equivalent to the ground state of chloroperoxidase 
compound I.
85 
The obvious interest in this highly reactive intermediate calls for the 
development of effective capture strategies (or trapping experiments), ideally in the 
natural catalytic cycle leading to the subsequent characterization of the “true” compound 
I form of these biological catalysts.   The present work is focused on efforts to generate, 
trap and spectroscopically characterize the elusive potent compound I intermediate of 
P450s under turn over conditions.  Specifically, utilization of chemically inert substrates 
of P450s were investigated as a possibly viable method of stabilizing the transient and 
highly oxidizing Fe(IV)=O porphyrin π-cation radical intermediate occurring in the P450 
catalytic cycle (6 in Figure 1.1.4) allowing for its characterization by RR methods. This 
strategy was initially applied to the P450cam system utilizing perfluoroadamantanone 
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(PFA) as a chemically inert substrate and later to the thermophilic bacterial P450, 
CYP119, where perfluorinated long chain fatty acids were employed as inert substrates.  
 
 
1.4.2 NMR spectroscopy characterization of isotopically labeled P450s 
 
 
This study aims at employing NMR methods to allow solution phase active site 
structure determination of P450s bearing isotopically labeled heme groups. Specifically, 
NOE experiments will be exploited to derive distances between heme reference points 
and substrate protons providing enhanced active site definition in the solution phase. 
NOE measurements will also be employed to establish spatial proximity between the 
heme reference points and active site residues.  
13
C-enriched P450 active side residues 
will also be exploited as reference points for establishing spatial proximity to substrate 
protons. Employing different substrates and derivation of distances between substrate 
protons and active site reference points will provide information on the flexibility and/or 
rigidity of the P450 active site. An extension of this approach to important drug 
metabolizing enzymes such as CYP2D6 has the potential to furnish valuable 
experimental restrictions in docking routines, which are commonly employed in 
determining the relative affinities of drug candidates. A recent and novel approach for the 
isotopic labeling of the prosthetic group in heme proteins has been exploited to produce a 
13
C analogue of the soluble bacterial cytochrome P450cam.
78
 Briefly, the HU227 strain of 
E. coli that lacks the δ-aminolevulinic acid (δ-ALA) synthase gene was employed in the 
heterologous expression of P450cam harboring a prosthetic group 
13
C labeled at the Cm 
and Cα positions (Figure 1.3.3) by growing cells in the presence of [5-13C] δ-ALA 
synthesized in four steps from [2-
13
C] glycine.
94,95
 This system has been employed in a 
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“proof of principle” exercise for the strategy of defining active site structure using NMR 
methods.  
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CHAPTER 2 UTILIZATION OF FLUORINATED SUBSTRATES TO 
STABILIZE COMPOUND I INTERMEDIATES OF CYTOCHROME P450 
2.1 Perfluorinated substrates of P450cam 
 
2.1.1 Introduction 
 
Initial efforts to employ chemically inert substrates as a possible strategy to 
stabilize and capture the compound I forms of P450s were performed using 
perfluoroadamantanone (PFA) 
96
 and the bacterial cytochrome P450cam.The major pitfall 
of using PFA as a P450cam substrate is its apparent lack of solubility in aqueous buffer. 
The alcohol derivative of PFA denoted PFA-ol, however has been reported to be soluble 
in a 1:1 methanol-water solution.
97 
Owing to limited quantities of PFA, optimization of 
the reduction procedure to obtain PFA-ol was done using 2-adamantanone. The product 
of 2-adamantanone reduction, 2-adamantanol, dissolved in a methanol/water solution (1:1 
ratio by volume), was shown to bind substrate-free P450cam with almost 100% spin state 
conversion of the heme from low spin to high spin (Figure 2.1.1). It was also established 
that reduction of PFA resulted in an impure product, which exhibited partial binding to 
substrate-free P450cam (Figure 2.1.2). The suggested reasons for the partial binding 
observed were thought to be false substrate stock concentration (due to the impure 
substrate) and that possibly PFA-ol only binds partially to P450cam as an inherent 
characteristic (thus not achieving 100% spin state conversion, see Figure 2.1.2). This 
required further optimization of the PFA reduction procedure; however the major setback 
was the dwindling quantities of stock starting material. In view of this drawback, 2-
adamantanone was used for further optimization of the reduction reaction and the results 
of such efforts are discussed in the following sections. 
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Figure 2.1.1 The UV-Vis spectra of 2-adamantanol binding to substrate-free P450cam 
 
 
 
Figure 2.1.2 The UV-Vis spectra of F-adamantanol binding to substrate-free P450cam 
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2.1.2 Optimization of PFA reduction procedure 
 
 
The optimization of PFA reduction was done using 2-adamantanone following the 
published procedure of Adcock et al. (1996).
97
 Specifically, a 15 mg portion of 2-
adamantanone was weighed and transferred to a glass vial. The vial was degassed by 
flushing with H2O/O2-free N2 gas for about 10 minutes, followed by addition of 370 µL 
of diethyl ether under N2 using a gas tight syringe. A solution of 1 M LiAlH4 in diethyl 
ether (130 µL) was then added to the solution of 2-adamantanone in diethyl ether. The 
vial was stirred for 2 h at about -2 °C and at room temperature overnight followed by 
addition of 100 µL of absolute ethanol under N2. The mixture was stirred for another 15 
minutes and then poured into a solution of 5 g of 98% H2SO4 (500 µL). The product was 
then extracted in diethyl ether and dried over P2O5 in a desiccator. The white product was 
sublimed at about 165 °C to give about 90% of pure 2-adamantanol (Figure 2.1.3). The 
improvement in the yield of 2-adamantanol (75 to 90%) suggests that an inert 
environment may be a required condition for PFA reduction.  
Reduction of PFA following the procedure just described gave transparent 
crystals stuck on the glass wall after evaporation of the ether extract (probably about 5 
mg). Efforts to sublime this product were unsuccessful as nothing was recovered at the 
cold finger possibly due to the small amount used. Considering that when 150 mg of PFA 
was used, about 60 mg of impure product was obtained and when further scaled down to 
60 mg only 15 mg was realized, utilizing 15 mg (as in the case described above) proved 
impractical for this deceivingly simple procedure. Also given that the reaction works 
excellently with 2-adamantanone giving yields of up to 90% pure 2-adamantanol even on 
the same small scale described, it may be argued at this point that 2-adamantanone has a 
different chemistry as compared to PFA and as such cannot be ideal for optimizing the 
37 
 
 
PFA reduction reaction. As mentioned previously, the dwindling quantities of PFA have 
proven to be challenge in these reactions. In an effort to advance the running aim of using 
chemically inert substrates to stabilize the compound I forms of P450s, an alternative 
route using CYP119 and perfluorinated fatty acids as possible inert substrates was 
adopted. 
 
 
Figure 2.1.3 H NMR of 2-adamantanone (top trace) and 2-adamantanol (bottom trace) in 
CDCl3 
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2.1.3 Cytochrome P450 119 (CYP119) 
 
CYP119, a thermophilic protein from the archaebacteria Sulfolobus solfataricus, 
has been shown to be stable under extreme temperatures and pressure.
98
 The reported 
melting temperature (90 °C) is 40 °C higher than the mesophilic P450cam and the 
enzyme has been demonstrated to exhibit hyperbaric stability, withstanding pressure of 
up to 200 MPa.
98–100
 Crystal structure studies of CYP119 have documented the presence 
of extended aromatic clusters not observed in mesophilic proteins and have been thought 
to confer the inherent thermal and pressure stability (Figure 2.1.4).
99–102
  The melting 
temperature was shown to decrease by approximately 10 °C when the aromatic clusters 
were disrupted by either a single or double mutation.
103
 
 
Figure 2.1.4 Crystal structure of CYP119 showing the aromatic residues thought to 
confer thermal stability
103
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Determination of the underlying factors conferring these unusual properties exhibited by 
thermophilic proteins can possibly be exploited in the engineering of stable mesophilic 
biocatalysts. In addition, the demonstrated structural stability of these proteins allows for 
mechanistic investigations, which are otherwise almost impossible in mesophilic P450s. 
In fact, at room temperature, the active site of such thermostable enzymes is possibly 
rigid, resulting in a possible slowdown of individual steps in the catalytic cycle.
104
 
However, the dioxygen complex of the substrate free CYP119 was shown to be unusually 
unstable with an autoxidation rate of 0.08 s
-1 
at 5 °C.105As would be expected, the 
substrate free dioxygen adduct of P450s are less stable compared to species in complex 
with substrate. However the observation in CY119 has in addition, been linked to the 
active site architecture in which the heme iron is more in plane than in the bacterial 
P450cam. Moreover a large deviation of the Fe−S bond from the heme axis and unusual 
ruffling of the prosthetic group have been proposed to account for the observed fast 
autooxidation rate.
105
 Structural investigations of the active sites of CYP119, P450cam 
and CYP102 showed that the thermophilic enzyme exhibits an open conformation with 
higher flexibility and greater solvent access than P450cam, but similar to CYP102.
98
 On 
the other hand, the compound I form of CYP119 produced by laser flash photolysis of the 
corresponding compound II (a product of peroxynitrite oxidation of CYP119) species has 
been reported to be stable with a lifetime of ~ 200 ms at 20 °C.91 However, later studies 
on peroxynitrite oxidation of CYP102 have shown that the intermediate generated is an 
iron-nitrosyl complex rather than the FeIVoxo.
106
 More recently, however, Green et al 
have utilized meta-chloroperoxybenzoic acid (m-CPBA) to generate the compound I 
intermediate in 75% yield permitting its spectroscopic and kinetic as discussed briefly 
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under Section 1.4.1.
85
 These findings make the thermophilic protein an attractive 
alternative to the ongoing work of using chemically inert substrates to stabilize what has 
been referred to as the Holy Grail of P450 intermediates or the so-called compound I.
91
  
The natural substrate for CYP119 remains unknown. However it has been shown 
to bind fatty acids ranging from C8-C20 in carbon chain length with lauric acid 
considered as a surrogate substrate exhibiting the highest binding affinity (Table 
2.1.1).
107,108
 
 
Table 2.1.1 The binding affinities of various surrogate substrates of CYP119
107
 
 
 
Lauric hydroxylation at 37 °C with chemically produced compound I species of CYP119 
have been reported to occur at positions 1, 2 & 3.107 Based on these observations, it 
is now being postulated that the perfluorinated analogues of these long chain fatty acids, 
which are commercially available, might possibly act as chemically inert substrates of 
CYP119. Chemical reduction of the ferric substrate-bound CYP119 (using perfluorinated 
fatty acids as inert substrates) was followed by binding oxygen to form the dioxygen 
adduct (4 in Figure 1.1.4). Cryoradiolysis of the dioxygen adducts of substrate bound 
CYP119 was employed in an attempt to generate, stabilize and spectroscopically 
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characterize the subsequent intermediates occurring in the catalytic cycle, of particular 
interest being the compound I form (6) of CYP119. 
  
2.2 Materials and Methods 
 
 
The plasmid encoding the CYP119 gene was kindly provided by the Sligar group 
and competent BL21 E.coli cells were purchased from Biolabs. Tryptone, yeast extract 
and Lauria-Bertani (LB) agar, used in the expression procedure described below, were 
purchased from Mo Bio Laboratories Inc. Lauric acid and ethylene glycol were obtained 
from Sigma Aldrich. Perfluorododecanoic acid (PFLA), perfluorodecanoic acid (PFDA) 
and perfluorooctanoic acid (PFOA) were purchased from Alfa Aesar and used without 
further purification. Ethylene glycol-d4 and D2O were purchased from Cambridge 
Isotopes. 
 
 
2.2.1 CYP119 Expression and Purification 
 
P450s are routinely produced by heterologous expression utilizing E.coli cells.
109
 
Basically, a self-replicating circular DNA, called a plasmid, bearing the sequences coding 
for the P450 of interest is introduced into E. coli competent cells (cells treated with CaCl2 
to make them porous; so they can take up foreign DNA) by a process known as 
transformation. The cells are then exploited to amplify the plasmid to produce large 
quantities of it. Usually, the plasmid contains sequences that code for an antibiotic 
resistance protein, such that only competent cells containing the foreign plasmid can 
grow on media supplemented with the respective antibiotic. Most commonly, the 
expression vectors (plasmids) contain inducible sequences upstream of the gene of 
interest, for example, the pCWori+ vector,
110
 which is widely used for P450 
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expression,
111
 exhibits sequences of a lac operon. The lac operon is involved in lactose 
metabolism in bacteria and its transcription is shutdown by a DNA binding protein 
known as a lac repressor protein, the operon is turned on in the presence of a lactose 
metabolite, allolactose, which binds the lac repressor protein. In the pCWori+, the lac 
operon, situated upstream of the P450 gene in the promoter region, is induced by addition 
of isopropyl β-D-1-thiogalactopyranoside (IPTG), an allolactose mimic, which binds to 
the lac repressor protein and turns on the lac operon. Thus, it induces expression of the 
downstream P450 protein.    
The CYP119-containing plasmid (provided by Sligar group at Urbana 
Champagne, IL) was transformed into BL21 cells (Biolabs) following the manufacturer’s 
protocol. A single colony from the overnight grown CYP119/BL21-LB agar plate was 
used to inoculate 10 mL of LB broth (supplemented with 100 g/mL ampicillin) as a 
starter culture for the expression of CYP119 performed according to a previously 
published procedure with minor modifications.
98
 Briefly, cells were grown overnight at 
37 °C and 250 rpm and used as 1 % inoculum in 10 mL of 2YT media (16 g tryptone, 10 
g yeast extract and 5 g NaCl per 1L) supplemented with 100 g/ml ampicillin. The 10 
mL culture was incubated at 37 °C and 250 rpm until the OD at 600 nm was about 0.3 
(about 2-3 h).  This early log phase culture was used to inoculate 1L of 2YT media (also 
supplemented with 100 g/mL ampicillin) grown at 37 °C and 250 rpm for 20 h. The 
cells were harvested by centrifugation at 8000 rpm for 10 minutes at 4 °C, giving an 
average of 12.5 g/L of wet cells. Cells were stored at -80 °C until needed. 
Cells were thawed and resuspended in 4 volumes (4 mL/g of wet cells) of lysis buffer (50 
mM Tris/HCl pH 8.0, 1mM EDTA, 4 mg/mL lysozyme, 16 U/mL DNase, 4 U/mL 
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RNase) and stirred gently for 4 h at 4 °C followed by centrifugation at 20 000 rpm for 1 h 
to remove cell debris. The supernatant was incubated at 75 °C for 15 minutes to remove 
some of the contaminating bacterial proteins. The precipitated bacterial proteins were 
spun down at 8000 rpm for 30 minutes and the supernatant slowly saturated to 40 % 
(NH4)2SO4 (243 g/L) and stirred gently for an hour at 4 °C. The precipitated proteins 
were removed by centrifugation at 8000 rpm for 30 minutes and the crude soluble 
CYP119 was precipitated following 100 % saturation with (NH4)2SO4 (469 g/L). The 
CYP119 pellet was resuspended in a minimum volume (~ 5mL) of 10 mM phosphate 
buffer (KPi), pH 7.2) and loaded onto Bio-gel P-100 column (3 x 40 cm) equilibrated and 
resolved in the same buffer. Fractions with Rz (A416/A280) values greater than 0.5 were 
pooled, concentrated and loaded onto DEAE 53 anion exchange column (3 x 12 cm) 
equilibrated in 10 mM KPi, pH 7.2. The column was washed with 6 column volumes 
(CV) of 10 mM KPi, pH 7.2 and the protein was eluted with a 10-100 mM KPi gradient 
at pH 7.0. Fractions with Rz > 1.5 were pooled and concentrated giving an average of 0.5 
mL of ~ 0.4 mM (per L of culture) of pure substrate free CYP119 (SFCYP119) with a 
low spin state heme iron (Figure 2.2.1).      
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Figure 2.2.1 The absorption spectra of the ferric substrate free form of CYP119 
 
2.2.2 Identification of a suitable inert substrate 
 
Lauric acid and its perfluorinated analogue were the first candidates due to the 
reported high binding affinity of lauric acid.
108
 Concentrated (12 mM) substrate stock 
solutions were dissolved in methanol and used to titrate substrate-free CYP119 
(SFCYP119). Substrate binding to SFCYP119 was monitored by spin state associated 
shifts of the Soret band from around 416 nm  down to 392 for the substrate free (low 
spin) and bound (high spin) forms, respectively. UV-Visble spectra were obtained using a 
Hewlett-Packard Model 8452 Diode Array Spectrophotometer. 
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2.2.3 Preparation of Oxy complexes 
 
Protein samples were prepared by mixing 20 L of 1 mM SFCYP119 (in 100 mM 
KPi, pH 8.0, 0.3 M NaCl), 7 L of glycerol (v/v) and 3 L of 25 mM PFDA (or Lauric 
acid) dissolved in ethylene glycol and transferred to an NMR tube. Deuterium 
substitution was achieved by equilibrating protein samples in D2O KPi buffer, pD 8.0, 0.3 
M NaCl for 2 days at 4 °C. Preparation of protein samples was essentially the same as 
above, with the only exception being utilization of deuterated glycerol and ethylene 
glycol. An in-house vacuum line assembly shown below was used in the preparation of 
dioxygen adducts of CYP119 (Figure 2.2.2).  The NMR tube containing the sample was 
frozen in liquid N2 and evacuated by opening valve1, while valves 2 and 3 remained 
closed. Small amounts of argon were added to the frozen sample by closing valve 1 and 
opening valve 2. The liquid N2 bath was removed from the sample and the sample was 
thawed and vortexed. This evacuation process was done 4 times.  While the sample is 
still immersed in liquid N2, in the 4
th
 evacuation cycle, valves 2 and 3 are both opened, 
such that a positive pressure is maintained. This is followed by dismantling of the 
removable part allowing addition of Na2S2O4 and O2 saturated buffer. The ferrous form 
of PFDA-CYP119 was prepared by incubating the respective ferric form with 1 L of 12 
mg/mL Na2S2O4 for about 30 minutes under argon atmosphere while formation of ferrous 
LA-CYP119 required 45 minutes incubation with 2 L of the dithionite solution. 
Reduction was monitored by changes in the Q-band region of the absorption spectra, the 
band near 550 nm is characteristic of the ferrous form of the heme protein (Figure 2.2.3).  
 
46 
 
 
 
Figure 2.2.2 Schematic of the vacuum line assembly utilized in the preparation of 
dioxygen adducts of CYP119 
 
 
Figure 2.2.3 The absorption spectra of ferric (bottom trace) and ferrous (top trace) lauric 
acid bound CYP119 
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The reduced samples were cooled down to – 20 °C by immersing the NMR tube in an 
ethanol/dry ice bath for 2 minutes while a positive argon pressure was maintained.  
Approximately 70 L of cold (-20 °C) 16O2-saturated buffer [100 mM KPi , pH 8.0, 30 % 
glycerol] was added to the cooled reduced protein followed by rapid mixing (using a 
vortex) for 10 s. The oxygenated samples were immediately frozen in liquid N2. 
Preparation of 
18
O2 adducts was achieved by rapidly mixing (10 s vortex) the reduced 
samples with ~ 100 L of 18O2-saturated buffer. The process was repeated for samples 
equilibrated in D2O KPi buffer with 
16
O2/
18
O2-saturated D2O KPi buffer. The formation 
of the dioxygen complex of substrate bound CYP119 was verified by RR at liquid N2 
temperature (vide infra). 
2.2.4 Cryoradiolytic reduction of CYP119 oxy complexes 
 
Cryoradiolytic reduction of the oxy complexes of CYP119 was performed as reported 
earlier
112
 with minor modifications. Specifically, frozen samples of oxy-ferrous CYP119 
were irradiated with 
60Co γ rays at 77 K and a dose rate of 92 Gy/min. The total 
irradiation time was 330 minutes, which translates to a total dose of ~ 3 Mrad or 30 kGy. 
Samples were kept in liquid N2 before, during and after irradiation. Irradiated and 
annealed (vide infra) irradiated samples were probed by EPR and RR spectroscopic 
methods 
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2.2.5 Resonance Raman Spectroscopy of CYP119 intermediates 
 
Resonance Raman spectra were obtained using a Spex 1269 spectrometer 
equipped with a CCD detector (Spec 10 from Princeton Instruments),  at liquid N2 
temperatures (77 K). The excitation lines employed for the oxyferrous samples before 
and after irradiation were 413 nm (Coherent Sabre Kr ion laser) and 441.6 nm (Kimmon 
Model IK4153RC He:Cd laser), respectively. Fenchone was used to calibrate all spectra, 
which were processed with Grams 32/AI (Galactic Industries, Salem, NH). Rayleigh 
scattering was removed by use of an appropriate Notch filter from Kaiser Optical. The 
power at the sample was approximately 1.5 mW. The NMR tube containing the sample 
was spun and the RR spectra were collected at liquid N2 temperature using 180
 
(back 
scattering) geometry in combination with a cylindrical lens, which focuses the laser beam 
on the sample as a line image to avoid local heating (Figure 2.2.4).
113,114
  
 
Figure 2.2.4 Schematic of RR instrumentation 
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2.3 Results and Discussion 
 
 
2.3.1 Inert substrate-CYP119 binding titrations 
 
 
 As mentioned previously, substrate binding was monitored by observing shifts of 
the Soret band from 416 nm (for substrate free protein) to 391 nm (substrate bound).  All 
the fatty acids employed were soluble in methanol; however, when the SFCYP119 was 
titrated using concentrated (12 mM) methanolic stock substrate solutions no significant 
spin state changes were observed in the absolute visible spectra of the protein even at 
elevated temperatures (37 °C) (Figure 2.3.1 and Figure 2.3.2). The difference spectra, 
however shows substrate binding associated spin state shifts [Figure 2.3.3 (data shown 
for lauric acid and its perfluorinated analogue)]. 
 
Figure 2.3.1 The absorption spectra of ~ 0.2 M SFCYP119 titration with LA (12 mM in 
ethylene glycol) at 37 °C; insert shows the molar ratio 
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Figure 2.3.2 The absorption spectra of ~ 0.2 M SFCYP119 titration with PFLA (12 mM 
in ethylene glycol) at 37 °C; insert shows the molar ratio 
 
 
Figure 2.3.3 The difference spectra of SFCYP119 titration with 12mM LA (A) and 
PFLA (B)     dissolved in methanol at 37 °C 
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As alluded to earlier, exogenous ligands coordinated to the heme iron on the distal 
site can be exploited to spectroscopically investigate structural details in the active site. 
The CO ligand was employed as a spectroscopic probe to monitor structural changes 
associated with substrate binding in heme proteins. Specifically, changes in the 
(Fe−CO) stretching frequency of the ferrous CO bound form of the enzyme can be used 
as evidence of substrate binding. The substrate free and bound samples of CYP119 were 
bubbled with CO, reduced by sodium dithionite and the (Fe−CO) frequency monitored 
by resonance Raman spectroscopy. Only slight changes in the (Fe−CO) mode were 
observed for CYP119 “bound” to lauric acid (LA), its perfluorinated analogue (PFLA) 
and perfluorodecanoic acid (PFDA), suggesting that the substrates may not be in close 
enough proximity to the heme group to cause any significant perturbation in the 
(Fe−CO) stretching mode (Figure 2.3.4). This is in contrast to the spectroscopic changes 
observed for the bacterial protein, P450cam, where the Fe−CO) stretching mode 
exhibits a 20 cm
-1
 shift from 464 to 484 cm
-1
 upon binding of substrate.
36,115
 On the other 
hand, the v(C-O) modes of PFLA and PFDA bound CYP119 occurring at 1950 and 1953 
cm
-1
 are upshifted by about 4 and 6 cm
-1
 respectively, suggesting slightly different 
substrate structure effects on the CO fragment (Figure 2.3.4).  
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Figure 2.3.4 RR spectra in the Low (left traces) and high (right traces) frequency regions 
of the ferrous CYP119-CO forms. SF; substrate free, LA; lauric acid bound, PFLA; 
perfluoro lauric acid bound and PFDA; perfluorodecanoic acid bound. 
 
Significant spin state changes were however observed when ~ 0.6 M SFCYP119 
was  incubated in 100 mM KPi, pH 7.0, 60% glycerol and ~2.5 mM LA at 50 °C (Figure 
2.3.5). PFLA on the other hand was not soluble in glycerol, but dissolved in ethylene 
glycol; however spectral changes were observed for the SFCYP119 incubated in 100 mM 
KPi with 30 % ethylene glycol (Figure 2.3.6), suggesting that ethylene glycol might be 
competing as a substrate.  No significant spin state changes were observed when 
SFCYP119 (in 100 mM KPi with 60 % glycerol) was titrated with volumes of ethylene 
glycol not exceeding 3 % at 50 °C (Figure 2.3.7). Under these conditions 
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perfluorodecanoic acid (PFDA) “dissolved” (at 50 °C the fatty acid melts) in ethylene 
glycol was shown to bind SFCYP119 with observable spin state changes (Figure 2.3.8). 
Specifically, a concentrated stock solution (50 mM) of PFDA “dissolved” in ethylene 
glycol was used to titrate ~ 0.6 μM SFCYP119 in 100 mM KPi, pH 7.0, 60 % glycerol in 
5 μL increments up to 20 μL, which translates to less than 1 % of ethylene glycol (v/v).  
 
Figure 2.3.5 The absorption spectra of ferric substrate free (black trace), ferric LA bound 
(blue trace) and ferrous-CO (red trace) forms of CYP119 
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Figure 2.3.6 The effects of ethylene glycol and glycerol on the absorption spectra of 
ferric SFCYP119 at 50 °C 
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Figure 2.3.7 Absorption spectra of SFCYP119 titration with ethylene glycol obtained at 
50 °C 
 
 
Figure 2.3.8 The absorption spectra of ferric SF (red trace) and PFDA bound CYP119 at 
50 °C. The insert shows changes in the Q-bands region upon substrate binding. 
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2.3.2 RR spectroscopy of substrate bound CYP119 
 
 
The high frequency resonance Raman spectra of the ferric substrate free and 
bound samples obtained at ~ 50 °C shows the corresponding partial spin state changes 
observed by absorption spectroscopy (Figure 2.3.9). The spin state marker 3 occurring at 
1502 cm
-1
 for the low spin SFCYP119, exhibits a clear down shift to 1488 cm
-1
 
(characteristic of a 5 coordinate high spin heme iron) upon substrate binding. As is 
evident in trace B of Figure 2.3.9, lauric acid binding causes the most significant (greater 
than 50%) spin state changes, a finding that is consistent with its high binding affinity 
(1.2 ± 0.2 M).107,108 In contrast PFDA results in a less significant spin state conversion, 
which may be due to the lower binding affinity of its non fluorinated analogue, decanoic 
acid (28 ± 2 M).107 However the spin state conversions in this current work observed at 
50 °C are significantly higher as compared to those reported for styrene-bound CYP119 
at 70 °C.
116
 The observed recalcitrance of CYP119 to spin state changes upon substrate 
binding is thought to be due to an unusually strong hydrogen bonding network stabilizing 
the distal water ligand in addition to the active site architecture discussed earlier
101
  
57 
 
 
 
Figure 2.3.9 The high frequency region of resonance Raman spectra obtained with 
406.7nm excitation at ~50°Cfor the SFCYP119 (A), Lauric acid bound CYP119 (B) and 
PFDA bound CYP119 (C).  
 
 
Given that the optimal growth temperature for the thermophilic bacteria from which the 
CYP119 gene was cloned is between78-86 °C, 
98,117,118
 it may be possible to obtain 100% 
spin state conversion with lauric acid binding at temperatures greater than 70 °C 
(assuming that lauric acid does not decompose). Although this might be crucial in 
explaining substrate binding in this thermophilic P450, it offers no advantage to our 
current efforts to stabilize and capture the elusive compound I form of CYP119, both 
which are performed at cryogenic temperatures. 
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The corresponding low frequency region spectra indicate changes to the modes 
associated with propionate and vinyl groups upon substrate binding. Specifically, lauric 
acid binding activates a second propionate bending mode occurring at 371 cm
-1 
(Figure 
2.3.10, trace B), which have been documented recently (in P450cam) to be degenerate 
with an out of plane 6 mode.
22
 The lower frequency vinyl bending mode (rather 
accurately described as pyrrole I or II deformations with vinyl contributions) occurring 
around 405 cm
-1
 is activated and up shifted with 2 and 3 cm
-1
 upon binding of LA and 
PFDA respectively. Consistent with the spin state conversion observed in the high 
frequency region upon binding of PFDA, activation of the lower frequency “vinyl 
bending mode” is less significant as compared to binding of LA.  
 
Figure 2.3.10 The low frequency resonance Raman spectra of ferric SF (A), LA bound 
(B) and PFDA bound (C) forms of CYP119 at ~50 °C 
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Interestingly, even with the observed spin state changes at 50 °C, no significant changes 
were observed in the (Fe-CO) upon substrate binding as noted earlier (Figure 2.3.11). 
Similar behavior has been observed in another bacterial cytochrome P450 isolated from 
Bacillus megaterium, the so-called P450BM3.
33
 
 
Figure 2.3.11 The resonance Raman spectra of the ferrous-CO for the substrate free (A), 
LA bound (B) and PFDA bound (C) CYP119 at 50 °C.  
 
 
Although substrate binding in CYP119 does not result in a full spin state 
conversion to the high spin as observed in the mesophilic P450cam, T1 NMR 
experiments of CYP119 with bound styrene has shown it to be within 4.4-4.5 Å of the 
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heme iron.
116
 On the other hand, the reported binding affinity of styrene is significantly 
lower than that of lauric acid, and indeed the hydroxylation of lauric acid, which has been 
studied extensively, suggests that it sits within reaction distance to the heme iron.
107,108
  
 
 
2.3.2.1 RR characterization of CYP119 dioxygen adducts before cryoradiolytic 
reduction 
 
The formation of oxy ferrous complexes of substrate bound (LA/PFDA) CYP119 
were confirmed by RR spectroscopy at 77 K. The high frequency spectra of the oxy 
complex of LA bound CYP119 shown in Figure 2.3.12, exhibits a broad band centered 
around 1135 cm
-1
, which has previously been interpreted as arising from the (16O-16O) 
stretching frequencies of different conformers of the Fe-O-O fragment. Indeed this mode 
exhibits isotope sensitivity shifting down by about 64 cm
-1
 upon 
18
O2 substitution, as can 
be clearly seen in the difference spectrum in the top trace of Figure 2.3.12, a finding that 
is consistent with previously reported spectra of trapped O2 adducts.
20,119
  The 
corresponding RR spectra of LA bound CYP119 in D2O buffer (Figure 2.3.13) suggests 
hydrogen bond interactions in the distal pocket between the bound dioxygen with either 
side chain residues or water molecules as evidenced by the H/D shift (2-3 cm
-1
) of the 
both 
18
O2 and 
16
O2 stretching modes. The dioxygen adduct of CYP119 in complex with 
the fluorinated substrate, PFDA exhibited similar RR spectral behavior in the high 
frequency region, with both (16O−16O) and (18O−18O) only slightly shifted down 
(2 cm
-1
) and centered around 1133 and 1068 cm
-1
 respectively (Figure 2.3.14). As 
observed for the LA bound dioxygen adduct of CYP119, both the 
16
O2 and 
18
O2 
stretching frequencies also demonstrated isotope sensitivity upon deuterium substitution 
of exchangeable protons (Figure 2.3.15), suggesting an H-bonded dioxygen species in the 
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distal pocket. A calculated model structure of the dioxygen adduct of CYP119 in the 
absence of substrate revealed similarities with the oxygenated intermediate of CYP101 
with the conserved threonine residue at position 213 within hydrogen bonding distance to 
the bound oxygen.
105
 In addition ,the active site water molecules, visualized in the high 
resolution crystal structure of ligand free CYP119, are possible hydrogen bond donors, 
these have been proposed to play a role in the catalytic scission of the bound dioxygen.
101
  
 
Figure 2.3.12 The high frequency RR spectra of the oxy ferrous complex of LA bound 
CYP119 in H2O buffer collected using the 413 nm excitation line at 77K 
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Figure 2.3.13 The high frequency RR spectra of the oxy ferrous complex of LA bound 
CYP119 in D2O buffer collected using the 413 nm excitation line at 77K 
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Figure 2.3.14 The high frequency RR spectra of the oxy ferrous complex of PFDA 
bound CYP119 in H2O buffer collected using the 413 nm excitation line at 77K 
 
64 
 
 
 
Figure 2.3.15 The high frequency RR spectra of the oxy ferrous complex of PFDA 
bound CYP119 in D2O buffer collected using the 413 nm excitation line at 77K 
 
The low frequency RR spectra of the dioxygen adduct of LA and PFDA bound 
CYP119 in H2O and D2O buffers are shown in Figures 2.3.16-2.3.19. Although spectral 
noise complicates identification of the (Fe−O2) mode, the difference spectrum of 
16
O2−
18
O2 provides some evidence for the (Fe−
16
O2) and (Fe−
18
O2) modes in the range 
expected for thiolate ligated heme proteins.
62
 The LA bound CYP119 (Fe−16O2) occurs 
around 533 cm
-1
 and exhibits sensitivity to 
18
O2 isotopic substitution, shifting with about 
34 cm
-1
 as expected (Figure 2.3.16). Interestingly, the difference spectrum of 
16
O2−
18
O2 
in D2O reveals an unusual distinct H/D shift, with both the (Fe−
16
O2) and (Fe−
18
O2) 
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modes shifting up by about 3 cm
-1
 upon deuterium substitution (top trace in Figure 
2.3.17), possibly suggesting H-bonding to the proximal oxygen. This observation is 
unusual in as much as such H/D shifts are reportedly small and normally not observable 
for the (M−O2) modes.
28,29,120–122
 The difference spectra of 
16
O2−
18
O2 of the PFDA 
bound CYP119 dioxygen complex in H2O buffer, shown in Figure 2.3.18, exhibits 
positive and negative broad bands centered around 524 and 490 cm
-1
, which makes it 
almost impossible to assign them to the stretching Fe –O modes. On the other hand, the 
dioxygen adduct of PFDA bound CYP119 in D2O buffer show similar behavior to the LA 
bound dioxygen species in the Fe−O stretching frequency region (Figure 2.3.19), with the 
16
O2 and 
18
O2 slightly upshifted by 3 and 5 cm
-1
 respectively, suggesting sensitivity of the 
bound ligand to different substrates. This observation has been reported earlier for 
CYP101, in which the (Fe−16O) mode for the camphor bound enzyme, occurring around 
541 cm
-1
 was down shifted to 537 cm
-1
in the dioxygen complex of adamantanone-bound 
P450cam.
62
 In summary, the RR data in both the high and low frequency spectral regions, 
document the successful formation of the dioxygen species of substrate bound CYP119 at 
liquid N2 temperature. Cryoradiolytic reduction of this species is expected to yield the 
peroxo/hydroperoxo intermediates (vide infra), which precedes the proton assisted 
scission of the O-O bond resulting in the generation of the compound I.  
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Figure 2.3.16 The low frequency RR spectra of the oxy ferrous complex of LA bound 
CYP119 in H2O buffer collected using the 413 nm excitation line at 77K 
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Figure 2.3.17 The low frequency RR spectra of the oxy ferrous complex of LA bound 
CYP119 in D2O buffer collected using the 413 nm excitation line at 77K 
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Figure 2.3.18 The low frequency RR spectra of ferric PFDA bound CYP119 and its 
16
O2 
and 
18
O2 adducts in H2O buffer 
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Figure 2.3.19 The low frequency RR spectra of the oxy ferrous complex of PFDA bound 
CYP119 in D2O buffer collected using the 413 nm excitation line at 77K. 
 
2.3.2.2  RR characterization of irradiated dioxygen adducts of CYP119 
 
Cryoradiolytic reduction was employed to deliver another electron to the 
dioxygen adducts of substrate-bound CYP119 in an attempt to generate the subsequent 
intermediates occurring in the P450s catalytic cycle. Briefly, oxy-ferrous samples of LA- 
and PFDA-bound CYP119 were irradiated, using 
60
Co, at a dose rate of 92 Gy/min for 
330 minutes. The irradiated substrate-bound CYP119 samples were characterized by RR 
at 77 K using the 442 nm excitation line, which is expected to selectively enhance the 
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peroxo- and hydroperoxo- intermediates. The low-frequency RR spectra of irradiated 
dioxygen adducts of LA-bound CYP119, in H2O and D2O buffers, are shown below 
(Figures 2.3.20 and 2.3.21). The difference spectra of 
16
O2-
18
O2, in both H2O and D2O 
buffers, shows residual oxy-ferrous complex of LA-bound CYP119 (top spectra in 
Figures 2.3.20 and 2.3.21). This is attributable to incomplete reduction of the oxy-ferrous 
samples during irradiation, probably because of weakening of the 
60
Co radiation source. 
Additionally, a negative band around 752 cm
-1
, is observed in both H2O and D2O 
samples. On the other hand, the 
16
O2-
18
O2 difference spectra of irradiated samples of 
PFDA-bound oxy-ferrous CYP119 show no evidence of residual dioxygen adducts; 
neither, unfortunately, is there any evidence for the expected peroxo/hydroperoxo 
intermediates (top trace of Figures 2.3.22 and 2.2.23). The band around 752 cm
-1
, for the 
LA-bound samples, might possibly be arising from the (18O−18O) mode, however, no 
corresponding (16O−16O) positive bands, expected in the 750-800 cm-1 region,20 were 
detected, making unequivocal assignment impossible. In fact, this band might be a heme 
mode coming from residual ferric form as observed in the low-frequency region of the 
spectra before irradiation (Figure 2.3.16). In addition, no isotopic sensitive bands were 
observed in the 520-580cm
-1
 region, where the (Fe−O2) mode is expected for the 
peroxo/hydroperoxo intermediates of P450s.
20
 The inability to detect either the 
peroxo/hydroperoxo intermediates, by RR at 77 K, might be due to warming, by the laser 
beam, at the surface of the sample. This, presumably, results in the decay of 
peroxo/hydroperoxo intermediates, through proton transfer and O-O bond cleavage 
leading to compound I and hydroxylation of LA. On the other hand, warming up 
irradiated samples of the dioxygen adducts of CYP119 in complex with a chemically 
inert substrate, PFDA, might result in accumulation of compound I on the surface of the 
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sample, however, to possibly undetectable levels. Low levels of oxy-ferrous in the 
samples may also explain the lack of accumulation of these intermediates to detectable 
levels. Noting that no ferrous form of the enzyme was detected following addition of 
oxygenated buffer (see Figures 2.3.12-2.3.15) during preparation of dioxygen adducts, it 
may be possible that the ferric form accumulated due to autooxidation.  Further RR 
investigation of irradiated samples in the high-frequency region showed high content of 
the ferrous form, presumably arising from radiolytic reduction of the ferric form, which 
accumulated during oxy-ferrous preparation by autooxidation (Figure 2.3.24) 
In an earlier study,
105
 Denisov et al. utilized EPR spectroscopy to characterize the 
intermediates produced following radiolytic reduction of the oxy-ferrous complex of 
substrate-free CYP119.  The authors observed a species with an EPR signature 
characteristic of the hydroperoxo intermediate (g-values = 2.29, 2.20, 1.95), which 
decays to the low-spin ferric form, via a ‘peroxide shunt’ pathway, upon gradual 
annealing at 170-195 K.
105
 Interestingly, when EPR spectroscopy was employed in the 
investigation of irradiated samples of the dioxygen adducts of LA- and PFDA-bound 
CYP119 (Figure 2.3.25), the respective spectra exhibited rhombic features (g = 2.28, 
2.16, 1.95) characteristic of the hydroperoxo intermediate of P450s.
20,30,105
 Unfortunately, 
a high content of the low-spin ferric form was also observed with g-values [2.40, 2.24, 
1.916], possibly formed during oxy-ferrous preparation, by autooxidation, as mentioned 
above. As can be seen in the EPR spectra (Figure 2.3.25 top trace) at 77 K, the low spin 
ferric content is higher in the PFDA-bound CYP119 samples; this may be attributed to 
the lower binding affinity of PFDA as compared to LA, such that autooxidation is 
possibly faster for the corresponding dioxygen adduct. Based on the EPR data, discussed 
above, it can be confirmed that input of one electron into the oxygenated intermediate 
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resulted in the formation of the hydroperoxo intermediate, however, to levels not 
detectable by RR at 77 K inasmuch as the only scattered light collected, is from the 
surface of the frozen samples. Annealing of the irradiated samples of LA- and PFDA-
bound CYP119 oxy-ferrous complexes resulted in the attenuation of the hydroperoxo 
signal (Figures 2.3.26 and 2.3.27), as previously observed in the substrate-free 
samples,
105
 however, both tubes reportedly broke during annealing, which explains the 
low S/N ratio in the spectra from 183-198 K. Interestingly, the hydroperoxo signal for the 
LA-bound sample is still present at 198 K, consistent with the higher initial content of 
oxygenated LA sample compared to the PFDA-bound sample as discussed above. Noting 
that these EPR studies were performed at 15 K, it may be possible that the signal of the 
compound I form of CYP119 could not be detected due to fast relaxation at this 
temperature.
123
 Rittle and Green,
85
 who utilized m-CPBA to artificially produce the 
compound I form of CYP119, were able to detect the EPR signals consistent with an 
S = 1 Fe(IV)=O that is exchange coupled with an S = ½ ligand based radical at 7.5 K. 
The authors utilized high microwave power to fully saturate signals from contaminating 
paramagnetic species and obtained the CYP119 compound I spectrum by difference. In 
any case, the detection of the hydroperoxo intermediate, in this present work, is 
especially encouraging in that there is a reasonable probability of trapping and 
spectroscopically characterizing the compound I by EPR at 7.5 K, using the approach 
outlined by Rittle and Green
85
 and possibly even by RR, provided sufficiently 
oxygenated ferrous forms of substrate bound CYP119 can be produced. 
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Figure 2.3.20 RR spectra of irradiated dioxygen adducts of LA-bound CYP119 in H2O 
buffer [
16
O2 (H2O) and 
18
O2 (H2O)] collected using the 442 excitation line at 77 K. The 
top trace shows the difference spectra of 
16
O2 – 
18
O2.  
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Figure 2.3.21 RR spectra of irradiated dioxygen adducts of LA-bound CYP119 in D2O 
buffer [
16
O2 (D2O) and 
18
O2 (D2O)] collected using the 442 excitation line at 77 K. The 
top trace shows the difference spectra of 
16
O2 – 
18
O2. 
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Figure 2.3.22 RR spectra of irradiated dioxygen adducts of PFDA-bound CYP119 in 
H2O buffer [
16
O2 (H2O) and 
18
O2 (H2O)] collected using the 442 excitation line at 77 K. 
The top trace shows the difference spectra of 
16
O2 – 
18
O2. 
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Figure 2.3.23 RR spectra of irradiated dioxygen adducts of PFDA-bound CYP119 in 
D2O buffer [
16
O2 (D2O) and 
18
O2 (D2O)] collected using the 442 excitation line at 77 K. 
The top trace shows the difference spectra of 
16
O2 – 
18
O2. 
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Figure 2.3.24 High-frequency RR spectra of irradiated ferric (top trace) and 
18
O2 (bottom 
trace) complex of PFDA-bound CYP119 in D2O buffer 
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Figure 2.3.25 EPR spectra of irradiated oxy-ferrous samples of PFDA-(top trace) and 
LA-bound (bottom trace) CYP119 at 77 K. The strong signal at g = 2 not shown 
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Figure 2.3.26 EPR spectra of irradiated samples of the dioxygen adduct of LA-bound 
CYP119 at different annealing temperatures. The strong signal at g = 2 is not shown 
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Figure 2.3.27 EPR spectra of irradiated samples of the dioxygen adduct of PFDA-bound 
CYP119 at different annealing temperatures. The strong signal at g = 2 is not shown 
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2.4 Summary 
 
 
The present work employed PFDA as an inert substrate of the thermophilic 
CYP119 in an attempt to generate, capture and spectroscopically characterize the 
compound I intermediate. CYP119 was shown, by absorption and RR spectroscopic 
methods, to bind LA and PFDA, inducing significant spin state changes at elevated 
temperatures (70 °C). However, no substantial substrate-binding associated shifts were 
observed in the (Fe−CO) for both substrates, possibly due to the open active site 
conformation of the thermophilic enzyme. Dioxygen adducts of substrate-bound samples 
of CYP119 were prepared at -20 °C, by rapidly mixing oxygen-saturated buffer with the 
ferrous form of the enzyme. Formation of the oxy-ferrous complex was confirmed by RR 
at 77 K where isotopic sensitive modes, consistent with the O−O bond stretching 
frequency, were observed. Cryoradiolysis was employed to generate the subsequent 
intermediates in the P450 catalytic cycle, specifically, the peroxo or hydroperoxo 
intermediates. RR investigation of the irradiated samples at 77 K, however, could not 
detect isotope sensitive bands in the regions expected for either peroxo/hydroperoxo 
intermediates. Residual oxy-ferrous form was observed in the 
18
O2 samples of LA-bound, 
possibly indicating inefficient reduction. On the other hand, EPR spectroscopy of 
irradiated samples confirmed generation of the hydroperoxo intermediate (g = 2.28, 2.16, 
1.95), however with a high content of the low-spin ferric form, possibly due to 
autooxidation (during oxy-ferrous preparation). The hydroperoxo species EPR signal was 
observed to decrease during stepwise warming from 77 to 198 K, however, tubes broke 
during annealing, making interpretation of the data difficult. Noting that the high content 
of the ferric low spin form in the irradiate samples could be due to autooxidation, 
production of sufficiently oxygenated ferrous substrate-bound CYP119 could be achieved 
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by reducing the mixing time (from 10 s to 5 s, for example) following addition of the 
oxygenated buffer. In addition, autooxidation may be decreased by reducing the cooling 
temperature from – 20 to – 30 ° C. This will however require increasing the glycerol 
content in the buffer. On the other hand, cryosolvents mixtures such a mixture of buffered 
ethylene glycol (20 %), methoxyethanol (70 %) could be employed to obtain less viscous 
protein solutions at – 50 °C.124  Detection of the hydroperoxo intermediate by EPR at 15 
K provides proof of reduction of the dioxygen adduct. Inasmuch as EPR detection of the 
artificially produced compound I was achieved at temperatures below 8 K, performing 
the above experiments at 7.5 K with irradiated samples containing an initial high content 
of the oxy-ferrous form, may possibly lead to the detection of the compound I form of 
CYP119 in complex to PFDA under turnover conditions for the first time.  
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CHAPTER 3 NMR DERIVED PARAMETERS FOR DOCKING SUBSTRATES 
TO CYTOCHROMES P450 
 
 
3.1 Introduction 
 
 
Cytochrome P450 2D6 (CYP2D6) is an enzyme responsible for metabolizing at 
least 20% of all drugs in the market, trailing behind only CYP3A4, which metabolizes at 
least 50%. The rather promiscuous behavior of these important drug metabolizing 
proteins is physiologically efficient in that it eliminates the need for the body to produce 
specific enzymes for each of the multitudinous pharmaceutical products or other 
xenobiotic compounds encountered and is attributed to the malleability of their active 
sites, which allows binding of different substrates (Table 3.1.1).
125–127
  
 
Table 3.1.1 List of CYP2D6 substrates
127
 
 
Amitriptyline 
Amoxapine 
Aripiprazole 
Atomoxetine 
Betaxolol 
Captopril 
Carvedilol 
Chloroquine 
Chlorpromazine 
Clomipramine 
Codeine 
Desipramine 
Dextroamphetamine 
Dextromethorphan 
Dihydrocodeine 
Doxepin 
Doxorubicin 
Duloxetine 
Flecainide 
Fluoxetine 
Fluphenazine 
Fluvoxamine 
Haloperidol  
Hydrocodone 
Imipramine 
Labetalol 
Lidocaine 
Lomustine 
Maprotiline 
Methamphetamine 
Methylphenidate 
Metoprolol 
Mexiletine 
Mirtazapine 
Moclobemide 
Nefazodone 
Nortriptyline 
Oxycodone 
Paroxetine 
Perphenazine 
Pindolol 
Pipotiazine 
Procainamide 
Promethazine 
Propafenone 
Propranolol 
Protriptyline 
Risperidone 
Sertraline 
Tamoxifen 
Tamsulosin 
Thioridazine 
Timolol 
Tolterodine 
Tramadol 
Trimipramine 
Venlafaxine 
Zuclopenthixol 
  
The presence of a basic nitrogen and a planar aromatic ring is a structural feature 
common to all known CYP2D6 substrates, as shown below in some representative 
structures (Figure 3.1.1).
128,129
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Figure 3.1.1 Four representative structures of CYP2D6 substrates with the typical basic 
nitrogen and a planar aromatic ring 
 
 
Unfortunately, efficient and accurate prediction of protein-ligand interactions by 
computational docking methods,
130,131
 which are routinely employed in determining the 
relative binding affinities of potential substrates and inhibitors, is compromised by the 
inherent flexibility of these binding sites. This, coupled to the fact that few crystal 
structures of protein-ligand complexes exist for these mammalian P450s, highlights the 
need for the development of strategies that can furnish valuable experimentally derived 
parameters for application in docking routines.  
Another long time problem of studying mammalian membrane bound P450s is the 
difficulty in expression and their lack of solubility in aqueous buffers such that the use of 
detergents is required to solubilize the proteins. In recent years soluble forms of 
mammalian proteins have been heterologously expressed in E. coli strains transformed 
with plasmid constructs bearing truncated P450 gene fragments  that lack the N-terminus 
(hydrophobic membrane spanning)  region.
128,132
  Rowland et al 
128
reported the crystal 
structure of a ligand-free (Figure 3.1.2) truncated form of the human CYP2D6 in which 
the N terminus of the wild type protein had been truncated at residue 34 and replaced 
with a more hydrophilic 2C3d N –terminus (residue 2-10). In order to increase the 
solubility, site directed mutagenesis was used to replace leucine surface hydrophobic 
residues at position 230 and 231 with the more hydrophilic aspartate and arginine 
residues, respectively. 
128
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Figure 3.1.2 The crystal structure of ligand-free CYP2D6
128
 
 
The ligand-free structure reported by Rowland et al differs significantly from the recently 
published structure of prinomastat (a substrate and potent inhibitor of CYP2D6) bound 
CYP2D6 (Figure 3.1.3).
132
 Differences were evident in  sheet 1, helices A, F, F`, G”, G 
and H as well as the helix B-C loop. Prinomastat bound CYP2D6 exhibits a closed cavity 
active site, which closely conforms to the substrate structure as compared to a rather open 
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active site of the ligand-free enzyme. This apparent induced fit model was attributed to a 
change in the direction and pitch of helix F and a turn at Gly-218, which is followed by a 
well defined helix F` not observed in the ligand-free structure (Figure 3.1.3).
132
  
 
Figure 3.1.3 Superposition of the prinomastat-bound (cyan) and ligand-free (light 
magenta) crystal structures. The arrow indicates the F’ helix present in the substrate 
bound structure.
132
 
 
 
Inasmuch as the number of crystal structures of protein-ligand complexes is likely 
to increase with the advent of better methods to express soluble mammalian proteins, 
adequate representation of the flexible P450s active sites could still be a challenge. Thus 
the potentially tremendous value of solution structure determination by spectroscopic 
methods cannot be over emphasized. The present study aims at exploiting NMR 
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spectroscopic methods to define the solution active site architecture of P450s. Thus, 
NMR measurements of P450s bearing isotopically labeled heme will be used to derive 
distances between reference points on the heme prosthetic group and substrate protons. 
Isotopically labeled P450cam was employed as a proof of principle exercise for this 
strategy of defining active site structure in mammalian P450s using NMR methods. More 
specifically, P450cam containing a heme group 
13
C-labeled at the methine carbons was 
heterologously expressed in E-coli cells grown on media supplemented with [5-
13
C] -
aminolevulinic acid ([5-
13
C] -ALA, a precursor in the heme biosynthesis). It is noted 
that use of this particular labeled precursor results in labeling of C and Cm carbons on 
the heme group (Figure 3.1.4), the latter of which will be useful for application of the 
nuclear Overhauser effect (NOE), an NMR technique used to determine spatial proximity 
between nuclei. NOEs will be measured for the methine protons (using 
13
C filter), 
providing needed data to determine relative distances from detectable substrate and active 
site amino acid residues protons. This will provide better definitions of substrate 
disposition in the active site and offer experimentally derived parameters, which are of 
potential value in docking calculations involving drug metabolizing enzymes. 
Incorporation of spectroscopically derived restrictions in docking routines will further 
refine these computational methods of defining the relative binding affinity and 
disposition of substrates in the active site of the protein 
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Figure 3.1.4 Supplementing bacterial media with [5-
13
C] -ALA will result in the 
biosynthesis of heme labeled at the Cm and Cα positions; black dots mark the positions of 
13
C enrichment
79
 
 
 
3.2 Materials and Methods 
 
 
The HU227strain of E.coli cells were kindly provided by Professor Gregory M. 
Raner of University of North Carolina Greensboro. CYP101 plasmids were isolated from 
E. coli BL21 cells using the Zippy plasmid prep kit (Zymo Research Corporation). The 
CYP2D6 construct was custom designed and synthesized by GenSript and cloned into 
pUC57. Subcloning of the CYP2D6 gene into the pCWori (from the CYP101 construct 
provided by Professor Paul R. Ortiz de Montellano of the University of California San 
Francisco) was also performed by GenSript. Phthalic anhydride and NaI were purchased 
from Sigma Aldrich while ethyl 3-bromopropionate, Zn-Cu couple and Pd(PPh3)4 were 
purchased from Alfa Aesar and used without further purification. The isotopically labeled 
[2-
13
C] glycine was purchased from Cambridge Isotope Laboratories. 
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3.2.1 Synthesis of [5-13C] -Aminolevulinic acid (ALA) 
 
 
Synthesis of [5-
13
C] -ALA with an average yield of 70% was achieved in four 
steps (Scheme 3.2.1) from [2-
13
C] glycine following published procedures, with minor 
modifications.
94,95
 Specific details of the procedure summarized are for the natural 
abundance -ALA. The 13C enriched heme biosynthesis precursor was synthesized from 
[2-
13
C] glycine after successful optimization of the procedure. 
 
Scheme 3.2.1 Synthesis of [5-
13
C] -ALA, the asterisk represents the 13C enriched carbon   
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Step 1: Synthesis of N-phthalimido acetic acid  
 
 
Well ground phthalic anhydride (~2 g, 13 mmol) and ~1 g (13 mmol) of natural 
abundance glycine were weighed and transferred to a 50 mL round bottom flask. The 
solids were mixed well before heating at ~180°C until the whole was melted (~ 5 min). 
This was followed by rigorous stirring for another 5 min, after which the mixture was 
cooled to give a yellow residue. The residue was dissolved in ~ 20 mL of hot water 
(~ 80°C) and left to recrystallize for about 2 h, after which needle-like transparent 
crystals had formed.  The crystals were filtrated and allowed to dry in a desiccator 
containing P2O5. The procedure was repeated using [2-
13
C] glycine to produce N-
phthalimido [2-
13
C] acetic acid. The 
1
H- NMR of the recrystallized product matched the 
published spectra of N-phthalimido acetic acid.
94
   
 
Synthesis of Ethyl 3-iodopropionate  
  
 
About 17 g (~110 mmol) of NaI were transferred to a 250 mL flame dried 2-neck 
round bottom flask, to which was added 10 mL (78 mmol) of ethyl 3-bromopropionate 
and 100 mL of 2-butanone. The flask was purged with argon for about 10 minutes and 
then refluxed at 90 °C for 16 h under argon.  After cooling the suspension was filtered, 
giving a reddish brown filtrate and a yellowish-white solid. The filtrate was evaporated 
using the rotary evaporator to remove 2-butanone, after which it was diluted with 
~ 80 mL of diethyl ether. This organic solution was washed with brine (3 x ~50 mL 
washings), followed by distillation to give ethyl 3-iodoprionate in 61% yield.  
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Step 2: Phthalimido acetyl chloride 
 
 
A 2.3 g (11 mmol) portion of natural abundance N-phthalimido acetic acid was 
weighed and transferred to a flame-dried 50 mL round bottom flask, to which 30 mL of 
SOCl2 was added. The mixture was refluxed at 80°C for 18 h after which the reaction 
was cooled and the excess SOCl2 was removed by rotary evaporator. The residue was 
dissolved in 5 mL of dry toluene and evaporated (this was done 3 times) to remove 
excess SOCl2. Immediately before use in the coupling reaction, described below, the 
product was dissolved in 5 mL of anhydrous toluene under Ar.  
 
Step 3: Ethyl phthalimido levulinate  
 
 
A 1.0 g portion of Zn-Cu couple was weighed and transferred to a flame-dried 2-
neck 50 mL round bottom flask. The flask was flushed with argon for 10 minutes 
followed by addition of dry toluene (1.2 mL) and 14 mL of N,N-dimethylacetamide 
(containing < 1% H2O) under argon. Ethyl 3-iodopropionate (2.0 mL, 12.4 mmol) was 
added to this suspension and the mixture was stirred for 15 h at 60°C followed by 
addition of a suspension of Pd(PPh3)4 (~530 mg) in 5 mL of dry toluene under argon. The 
reaction flask was then stirred for 5 min at 60°C followed by the addition of a 5 mL of a 
suspension of partially dissolved phthalimido acetyl chloride in dry toluene. The reaction 
was stirred for an additional 25 min and then diluted with 300 ml ethyl acetate. This 
mixture was washed with 1 N HCl (250 mL), saturated NaHCO3 (250 mL) and brine (250 
mL), dried over MgSO4, filtered and evaporated. The resulting reddish-brown residue 
containing the desired product, as judged by 
1
H NMR,
94
 was passed through a silica gel 
(60) column (15″ x 1.8″) using ethyl acetate: hexane (1: 1) solvent system. The fractions 
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were checked by TLC; those with a single spot were pooled and the presence of the 
desired product verified by 
1
H NMR and melting point measurements (vide infra).  
 
 
Step: 4 Aminolevulinic acid (ALA) 
 
 
A 480 mg (1.60 mmol) portion of ethyl phthalimido levulinate was transferred to 
a 25 mL round bottom flask followed by addition of ~ 6 mL of 6 N HCl. The mixture was 
refluxed at 110 °C for ~24 h. After cooling to room temperature, the reaction mixture was 
filtered (crystals of phthalic acid, ~180 mg) and the resulting aqueous filtrate was washed 
3 times with diethyl ether (10 mL). The aqueous filtrate was evaporated giving a brown 
residue, which was recrystallized from an ethanol-ether solution (3 mL).  This procedure 
was repeated using ethyl 5-N phthalimido [5-
13
C] levulinate to yield [5-
13
C] -ALA in 
~ 70% yield. 
 
 
3.2.2 Expression of [5-13C] -ALA P450cam 
 
 
Viability of HU227 E-coli cells 
 
 
The cells of the -ALA synthase-deficient E-coli strain, HU227 obtained as a gift 
from Dr. Raner (University of North Carolina Greensboro) require CaCl2 treatment
133
 to 
render them competent prior to transformation with the P450cam gene. The viability of 
the cells was tested by aseptically growing them overnight on LB plates supplemented 
with the natural abundance -ALA. After 12 h of incubation at 37 °C, several colonies 
appeared in LB plates supplemented with 20 mg/L -ALA whilst no growth was 
observed in plates without -ALA (negative control plates). Single colonies were picked 
93 
 
 
to inoculate 50 mL of LB medium containing 20 mg/L ALA. The cells were shaken (250 
rpm) at 37 °C until an OD600 of 0.5 (~3 h). The cells were diluted further by spreading 10 
µL on LB plates supplemented with ALA and grown overnight at 37 °C. Single colonies 
were picked and the process repeated as described above. Plates with well separated 
colonies were stored at 4 °C prior to preparation of competent cells. 
 
Preparation of Competent cells  
 
 
A single colony of HU227 cells was picked and used to inoculate 100 mL LB 
medium containing 20 mg/L ALA. The cells were grown (at 225 rpm and 37 °C) to an 
OD600 of 0.5. Ideally for normal E. coli strain, cells should reach an OD600 of 0.5 after 3h 
of vigorous shaking; however the cultures in this work reached an OD600 of less than 0.1 
after ~5h of incubation, possibly indicating high level of cell deaths of this fragile strain 
of E. coli.  The cells were left at 4 °C overnight and then transferred to the shaking 
incubator at 37 °C, finally reaching an OD600 of 0.5 after about 2 h. The cells were 
transferred to ice cold 50 mL polypropylene tubes and incubated on ice for about 10 
minutes. The cells were recovered by centrifugation at 4100 rpm for 10 min and the 
medium decanted. The tubes were inverted on a wad of paper towel to drain away all 
traces of media. Each pellet was resuspended in 30 mL of ice-cold MgCl2-CaCl2 solution 
(80 mM Mg Cl2, 20 mM CaCl2) and mixed by gently swirling. The cells were recovered 
again by centrifuging at 4100 rpm for 10 minutes followed by decantation of the medium. 
All traces of the media were drained away by inverting the tubes on a wad of paper towel 
for about a minute. Each pellet from the original 50 mL culture was resuspended by 
gently swirling in 2 mL of ice-cold 0.1M CaCl2. Frozen stocks of HU227 competent cells 
were prepared by gently mixing each 2mL suspension with 70 µL of DMSO and 
94 
 
 
incubating on ice for 15 min followed by an additional 70 µL of DMSO. Aliquots of 
50 µL were transferred to pre-chilled microcentrifuge tubes using sterile chilled pipette 
tips and immediately frozen using liquid nitrogen. Cells were stored at -80 °C overnight 
prior to transformation as described below. 
 
Transformation of HU227 cells and expression P450cam 
 
The CaCl2 treated HU227 competent cells were transformed with the pCWori 
plasmid harboring the P450cam gene and selected for ampicillin resistance on Luria-
Bertani (LB) agar plates supplemented with -ALA (20 mg/L). A single colony was 
utilized to initiate expression of P450cam. Specifically, transformed HU227cells were 
grown (from a single colony) overnight at 37 °C in 10 mL LB broth supplemented with 
ampicillin and -ALA (20 mg/L). About 1% of the overnight culture was used as 
inoculum in 100 mL of 2YT medium (16 g tryptone, 10 g yeast extract and 5 g NaCl per 
1L) also supplemented with ampicillin and -ALA. The cells were grown to OD600 = 0.8 
at 37 °C and 250 rpm followed by addition of 1 mM isopropyl -D-1-
thiogalactopyranoside (IPTG) and 0.5 mM -ALA. Induction was allowed to proceed for 
24 h at room temperature and shaking at 190 rpm. After 22 h of induction, solid camphor 
was added to the culture to a final of concentration of 1 mM. The cells were harvested 
after 24 h of induction by centrifugation at 8000 rpm for 10 min, weighed (12 g/L of 
culture) and frozen at -80°C. Cells were thawed, resuspended in 3 volumes (3 mL/g of 
wet cells) of lysis buffer [50 mM Tris-Cl (pH 7.4), 25 mM KCl, 1 mM PMSF, 1 mM 
camphor, 1 mM EDTA, 1 mg/mL lysozyme, 1 g/mL leupeptin, 1 mg/mL pepstatin, 
1 mg/mL antipain, 32 Units/mL DNase I, 3 Units/mL RNase A)] and incubated at 4 °C 
for 30 min followed by sonication. Cells were centrifuged at 20 000 rpm for 2 h and the 
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clarified lysate was concentrated  to about 5 mL and loaded onto an anion exchange 
(DEAE-cellulose) column (3 x 15 cm) equilibrated with 50 mM Tris-HCl (pH 7.4), 25 
mM KCl, 1 mM camphor (running buffer). The bound protein band was washed with 6 
column volumes (CVs) of the running buffer and eluted by a linear gradient using 50 mM 
Tris-HCl (pH 7.4), 300 mM KCl, and 1 mM camphor as the elution buffer. Fractions with 
an Rz (A391/A280) > 0.5 were pooled and concentrated (to about 5 mL) followed by 
addition of ammonium sulfate (75 mg/mL) The pooled fractions were loaded onto a 
hydrophobic interaction (Phenyl Sepharose) column equilibrated with 50 mM Tris-HCl 
(pH 7.4), 25 mM KCl, 1 mM camphor, 25% (NH4)2SO4 and washed with 6 CVs of the 
same buffer. The elution buffer contained 50 mM Tris-HCl (pH 7.4), 25 mM KCl 
and1 mM camphor. Elution of the bound protein was achieved by applying a linear salt 
gradient 25-0% (NH4)2SO4 and fractions exhibiting Rz > 1.4 were pooled and 
concentrated to about 2 mL. Ammonium sulfate was removed by exchanging the buffer 
to 30 mM KPi (pH 7.4), 100 mM KCl, 1 mM camphor D2O using microsep centrifugal 
devices. Equilibration of samples in D2O buffer was performed as an initial step for 
preparing samples for NMR measurements. When expression was scaled up to 1 liter of 
2YT medium, 0.3 mL of ~ 0.4 mM pure P450cam (Rz = 1.5) was obtained. Protein 
concentration was calculated from the absorption spectra, using an extinction coefficient 
of 391 = 102 mM
-1
cm
-1 
for the camphor bound CYP101.
134 
The preceding procedure was 
repeated using [5-
13
C] -ALA resulting in the expression of 13C-labeled P450cam (0.5 
mL of ~ 0.2 mM, Rz 1.5; Figure 3.2.1). 
96 
 
 
 
Figure 3.2.1 The absorption spectrum of high spin ferric cytochrome P450cam 
 
3.2.3 CYP2D6 expression 
 
Rowland et al (2006)
128
 described modifications for the CYP2D6 construct, 
which included N-terminus truncation (truncated at residue 34 and residues 2-10 of 2C3d 
inserted at the N terminus), addition of 4 histidines at the C-terminus and mutations of the 
hydrophobic residues at positions 230 and 231. They reported high level expression of 
soluble holo-CYP2D6 using this truncate (truncate 5) in E. coli (DH10B strain).
128
 These 
modifications described above were used to design a replica of truncate 5 using the wild 
type gene sequence (NCBI Gene bank: ADF36476.1). Codons for the modifications were 
derived from reverse translation of the amino acid sequence of 2C3d (for the N terminus) 
and L230D/L231R mutations and optimized for the E.coli expression system (see Figure 
3.2.2 for the gene and protein sequences below). NdeI and XbaI restriction endonuclease 
recognition sites where introduced at the N and C termini respectively to allow subloning 
into the pCWori+ expression vector. 
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Figure 3.2.2 The gene (top) and protein (bottom) sequences of truncated CYP2D6 
 
The construct was commercially synthesized (by GenSrcipt) and delivered as a 
lyophilized pUC57 plasmid. The gene was subcloned into pCWori (also by GenSript) and 
transformed into BL21 and competent HU227 cells for production of the natural 
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abundance and [5-
13
C] -ALA labeled CYP2D6 respectively. The detailed expression 
procedure is outlined below. This procedure (with slight variations) has been used to 
successfully produce [5-
13
C] -ALA CYP101 as already discussed earlier. 
Transformed BL21cells were grown (from a single colony) overnight at 37 °C in 10 
mL LB broth supplemented with 100 mg/L ampicillin. 1% of the overnight culture was 
used as inoculum in 100 mL of TB medium [(12 g tryptone, 24 g yeast, 9.4 g K2PO4, 2.2 
g KHPO4, 4 mL glycerol)/L]  supplemented with ampicillin (100 mg/L), 20 mg/L -
ALA, 1 mM thiamine and trace elements [(27 g FeCl3
.
6H2O, 2 g ZnCl2
.
4H2O, 2 g  
CoCl2
.
6H2O, 2 g Na2MoO4
.
2H2O, 2 g CaCl2
.
2H2O, 1 g CuCl2, 0.5 g H3BO3, 100 mL HCl 
conc)/L] solution (3 mL per liter of culture).
135
 The cells were grown at 30 °C with 
shaking at 250 rpm to an OD600 = 0.6, followed by addition of 1 mM IPTG. Induction 
was allowed to proceed for 24 h at room temperature and shaking at 190 rpm. The cells 
were harvested by centrifugation at 8000 rpm for 10 min, weighed (12 g/L of culture) and 
frozen at − 80°C.  Expression of CYP2D6 was checked by CO difference spectra of the 
total cell lysate. Briefly, cells (~ 1 g) were freeze-thawed twice and resuspended in 4 mL 
of 400 mM KPi buffer (pH 7.6), 20 % glycerol, and 1 mM CHAPS. The lysate (~ 4 mL) 
was clarified by centrifugation at 20 000 rpm for 10 min. The clarified solution (~ 3 mL) 
was transferred to a gas tight 10 mm cuvette, bubbled with CO gas for ~ 20 min and 
treated with excess Na2S2O4 (10 L of 50 mM dithionite solution). The absorption 
spectrum was collected using the Hewlett-Packard Model 8452 Diode Array 
Spectrophotometer. The supernatant, presumably containing the cytosolic fraction of the 
truncated CYP2D6, was obtained following cell lysis performed according to a published 
procedure.
128
 The cytosolic fraction in 400 mM KPi, pH 7.4, 20% glycerol and 10 mM -
mercaptoethanol buffer, was loaded onto a Ni
2+
-nitrilotriacetic acid column equilibrated 
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with the same buffer and washed with 6 CVs washing buffer containing 400 mM KPi, pH 
7.4, 20% glycerol, 10 mM -mercaptoethanol, 50 mM glycine and 100 mM NaCl. The 
bound fraction was eluted using a linear gradient 0-100 mM EDTA (and simultaneously 
glycine concentration of 50 to 0 mM) of elution buffer (400 mM KPi, pH 7.4, 20% 
glycerol, 10 mM -mercaptoethanol, 100 mM EDTA), as previously reported.128 
Fractions exhibiting spectral characteristics of CYP2D6 (Soret band at 415 nm) were 
pooled, concentrated and checked for P450 (and any P420) by CO difference spectra. The 
procedure described above was scaled up and applied to BL21 cells transformed with the 
pCWori+ plasmid bearing the truncated gene of CYP2D6. 
 
3.2.4 Resonance Raman Spectroscopy of [5-13C] -ALA P450cam 
 
RR measurements of ferric forms of the natural abundance and 
13
C enriched 
P450cam were essentially the same as described earlier except that the 406 nm excitation 
line from the Kr+ laser (Coherent Sabre) was used with ~ 15 mW at the sample and that 
spectra were collected at room temperature.  
 
3.2.5 NMR spectroscopy 
 
1
H and 
1
H-
13
C heteronuclear single/multiple-quantum correlation (HSQC/HMQC) 
NMR measurements were performed using Varian 600 MHz equipped with a triple-
resonance cryoprobe while 1 D 
13
C NMR experiments were done on the Varian 400 MHz 
instrument. NMR samples contained ~0.4-1 mM P450cam (both for the natural isotopic 
abundance and 
13
C enriched camphor bound P450cam), 30 mM KPi, pD 7.4, 100 mM 
KCl, 1 mM camphor. The protein concentration was determined spectrophotometrically 
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using an extinction coefficient of =102 mM
-1
cm
-1 
for the camphor bound P450cam.
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Substrate free samples were prepared by passing the camphor bound protein through a 
sephadex G25 column equilibrated with 50 mM MOPS buffer followed by equilibration 
with 30 mM KPi, pD 7.4, 100 mM KCl. One dimensional 
1
H NMR experiments were 
performed using 0.1 s acquisition time, 20 ms relaxation delay with a total of 256 scans at 
25 °C and were collected before and after 13C and 2 D NMR measurements to verify 
sample integrity. A total of 400 000 scans were collected for the 
13
C NMR experiment at 
20 °C for both the natural abundance and 13C enriched substrate bound P450cam. The 1 D 
version of 
1
H-
13
C HSQC measurements for the natural abundance and 
13
C enriched 
substrate bound and free P450cam were performed at 20 °C using 23 ms acquisition time, 
0.2 s relaxation delay and JCH = 200 Hz; a total of 240 000 scans were collected. 
1
H-
13
C 
HMQC experiments, with the decoupler turned off, were performed using 50 ms 
acquisition time, 10 ms relaxation delay and JCH = 300. 
1
H-
1
H NOESY was obtained with 
pre-saturation delay of 100 ms, acquisition time of 43 ms, 10 ms mixing time, JCH = 600 
and 7200 number of scans. All 1D NMR data were processed with the MestReNova 
NMR processing software with 10 Hz exponential line broadening while 2D spectra were 
processed using the NMRPipe software. 
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3.3 Results and Discussion 
 
3.3.1 Synthesis of [5-13] -ALA 
 
Step 1: Synthesis of N-phthalimido acetic acid  
 
The first step in the synthesis of ALA was relatively straightforward and complete 
in 5 min giving pure (see 
1
H NMR in Figure 3.3.1) N-phthalimido acetic acid in ~86% 
yield (~2.3 g, 11.2 mmol) with a melting point between 192-197 °C (reported mp is 
between 193-195 °C)
94 
after recrystallization from hot water  
 
Figure 3.3.1 
1
H NMR of natural abundance (B) and 
13
C enriched (A) N-phthalimido 
acetic acid dissolved in CDCl3 
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Synthesis of Ethyl 3-iodopropionate  
 
 
Distillation of the reaction mixture of NaI and 3-bromopropionate (in 
2-butanone), after refluxing for 16 h at 90 °C, resulted in 61% yield (10.93 g) of 
3-iodopropionate. The 
1
H NMR (Figure Figure 3.3.2) shows a slight down-shift of the 
proton signals (a) located on C3 that is directly bonded to the halogen, indicating the 
success of the transhalogenation reaction. 
 
Figure 3.3.2 
1
H NMR of ethyl 3-bromopropionate (A) and ethyl 3-iodopropionate (B) in 
CDCl3  
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Step 2: Phthalimido acetyl chloride 
 
 
(a) Initial attempts 
 
 
Initial attempts to synthesize phthalimido acetyl chloride following the methods 
of  Kajiwara and Iida
94
, resulted in a product that dissolved partially in anhydrous 
toluene, which was used to remove traces of SOCl2. Removal of the solvent resulted in a 
dirty-yellowish-white solid. Noting that, in addition to the desired product, acetyl 
chloride, gaseous SO2 and HCl are produced in this reflux, these may possibly react with 
rubber septa (the reaction was initially set up as a closed system under Ar) resulting in the 
dirty yellowish-white color observed. When an open system was used, the residue 
obtained after removal of SOCl2 dissolved in dry toluene and was yellowish-white in 
color. The average yield from the three trials performed on this reaction was ~ 95 % 
(2.1 g, 2.2 g, 2.2 g) and the purity improved on the third trial as judged by 
1
H NMR and 
melting point measurements. The product was left to dry in a desiccator containing P2O5. 
The acetyl chloride was flushed with argon for ~ 10 min and dissolved in 5 mL (the 
dissolution was only partial) dry toluene immediately before being coupled with 
2-ethoxycarbonylethylzinc iodide as described in the following section (Step 3).  It was 
noted (by 
1
H and 
13
C NMR, Figure 3.3.3) after failed repeated attempts to dissolve 
phthalimido acetyl chloride (obtained after refluxing phthalimido acetic acid and SOCl2 
at 80 °C for 18 h
94
), that when left for ~3 days contained about 25% phthalimido acetic 
acid, which suggests it is not stable. Phthalimido acetic acid is not soluble in toluene, 
which may explain the partial solubility mentioned above.  
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(b) Revised procedure for the synthesis of phthalimido acetyl chloride 
 
 
This same reaction was reported by Deng et al., 2008
137
 to be complete in about 3 
h at a lower temperature of 60 °C, followed by removal of excess SOCl2 at 55 °C (~ 70 
°C was used in the reactions described above). They found that the product was partially 
decomposed at higher temperatures, which might explain the lower yields obtained in the 
coupling reactions (vide infra). In addition, they pointed out the need to use the product 
immediately after dissolution in an anhydrous solvent.
147
 When this procedure (of Deng 
et al)
137 
was followed (10 mlL of SOCl2 was used in the reflux), the reaction was 
incomplete after 3 h as judged by 
1
H NMR. It was noted that the reaction is almost done 
after 2 h when heated to 75 °C and complete after 3 h. Removal of the excess SOCl2 was 
done under reduced pressure at ~ 55 °C. The resulting yellow crystalline product was 
dissolved in 3 mL of dry toluene and evaporated (done twice). A few mg of the product 
was dissolved in CDCl3 for 
1
H & 
13
C NMR measurements and the rest of the sample was 
left to dry in a desiccator overnight to check its stability. The product was found to be 
stable overnight (by 
1
H and 
13
C NMR, see Figure 3.3.4), giving enough time to couple 
with the 2-ethoxycarbonylethylzinc iodide reaction, which runs overnight for 15 h.  
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Figure 3.3.3 The 
1
H NMR spectra of a mixture of phthalimido acetyl chloride and its 
acid derivative (x; ~ 25% of phthalimido acetic acid). The inset shows the extra 13C 
signal (x) from the acid derivative  
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Figure 3.3.4 The 
1
H NMR of natural abundance (top trace) and 
13
C enriched (bottom 
trace) pure phthalimido acetyl chloride (in CDCl3) after 3 h of refluxing phthalimido 
acetic acid and SOCl2. Inset shows the 
13
C NMR spectra of the natural abundance 
phthalimido acetyl chloride 
 
Step 3: Ethyl phthalimido levulinate  
 
 
(a) Initial attempts 
 
 
1
H NMR of the chromatographed product of the coupling reaction of N-
phthalimido acetyl chloride and 2-ethoxycarbonylethylzinc iodide exhibited chemical 
shifts of the desired product, ethyl phthalimido levulinate; however, very low yields were 
obtained. Verification of desired product in chromtographed fractions was also done by 
absorption spectroscopy, whereby the spectrum of the ethyl phthalimido containing 
fractions (judged by 
1
H NMR and reported mp)
94
 had a maximum at ~ 290 nm (Figure 
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3.3.5), The low yields obtained could be attributed to the partially dissolved phthalimido 
acetyl chloride, which as explained above is not stable and easily reverts to the acid form. 
The use of completely dry solvents and oxygen free atmosphere was discovered to be 
crucial for obtaining better product yields. Improved yields of up to 800 mg (~25%) were 
obtained when the coupling reaction was done in a glove box, but still employing 
partially dissolved phthalimido acetyl chloride. This was however still very low 
compared to the 92% reported by Kajiwara and Iida (2002).
94
 Campbell and Johnston 
(1989)
95
 in their synthesis of 5-amino [4-
14
C] levulinic acid, reported this coupling 
reaction as the key step. They used 200 mL of ethyl acetate to dilute the reaction mixture 
and used only 50 mL in their washings. In the present work the lower yields obtained 
could possibly be due to loss during the washings therefore smaller volumes of the 
aqueous washes were adopted in the modified procedure briefly described below.  
 
(b) Improved procedure 
 
 
Ethyl 3-iodopropionate (~ 2.5 mL) was added to a suspension of Zn-Cu couple 
(1.35 g) in ~27 mL of dry toluene and ~ 2 mL of anhydrous dimethylacetamide under 
argon. The whole was stirred for 1 h at room temperature and at 60 °C for 4.5 h under Ar 
instead of 15 h. To this flask was added a suspension of 418 mg Pd(PPh3)4 in 5 mL of dry  
toluene under argon, followed by stirring for 5 minutes at 60 °C, after which a solution of 
phthalimido acetyl chloride (~ 2 g) in 5 mL of dry toluene was added and stirring 
continued for an additional 10 min; longer times (15 min >) have been reported to 
produce side products, which makes it necessary for stringent purification steps to be 
employed.
95
 The reaction was diluted with ethyl acetate (~200 mL), washed with 1 N 
HCl (50 mL), saturated NaHCO3 (50 mL) and brine (50 mL), dried over anhydrous 
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MgSO4 and filtered. An orange residue (crude product) was obtained; note the difference 
in the color from reddish brown that was discussed earlier. Removal of solvent by rotary 
evaporator followed by recrystallization from absolute ethanol (5 mL) gave white crystals 
of pure ethyl phthalimido levulinate in 75% yield (average of 2 trials).  
 
 
Figure 3.3.5 
1
H NMR of 
13
C enriched ethyl phthalimido levulinate dissolved in CDCl3 
(s); Insert shows the absorption spectrum of fractions containing pure ethyl phthalimido 
levulinate 
 
Step: 4 Aminolevulinic acid (ALA) 
 
 
Hydrolysis of ~ 480 mg of ethyl phthalimido levulinate in 6N HCl resulted in 
~ 140 mg (65 %) white crystals of pure ALA after recrystallization from ethanol-ether 
(Figure 3.3.6). Approximately 20 mg of the starting material, ethyl phthalimido 
levulinate, was recovered following evaporation of the ether layer, indicating a 
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reasonably high conversion rate; based on the theoretical yield calculations, ~ 60 mg of 
product was lost possibly during the washings (washing of the aqueous layer with diethyl 
ether following filtration of the hydrolysis reaction mixture) and/or the recrystallization 
step described section 3.2.1. 
  
 
 
Figure 3.3.6 The 
1
H NMR spectra of the natural abundance - ALA (bottom trace) and 
[5-
13
C] -ALA (top trace) dissolved in D2O; insert shows the 13C NMR spectrum of the 
natural abundance -ALA 
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3.3.2 CYP2D6 Expression 
 
 
This initial trial expression of CYP2D6 from BL21 cells transformed with pUC57 
bearing the truncated gene of the protein was confirmed by the CO difference spectra of 
the total cell lysate (Figure 3.3.7). When the cytosolic fraction was applied onto the 
Ni
2+ 
-nitrilotriacetic acid column only a small fraction was bound and the eluted fraction 
exhibited spectral characteristics consistent with a hexacoordinated heme species (top 
trace of Figure 3.3.8).
138,139
 Upon elution with the gradient described above, the initially 
bound fraction, however, exhibited an absorption maximum at around 415 nm (middle 
trace of Figure 3.3.8), which is characteristic of low spin heme protein. Expression of 
CYP2D6 from glycerol stocks could not be confirmed in subsequent trials; rather, an 
absorption spectrum characteristic of a six coordinated heme species, which was resistant 
to reduction, was observed (Figure 3.3.9). It is possible that the C-terminus histidine of 
one protein molecule coordinates to the heme iron of another CYP2D6 molecule resulting 
in a hexacoordinated species. Additionally, the observed optical properties of the total 
cell lysate could be arising from spontaneous mutations (probably deletion during 
storage) in the CYP2D6 gene from the frozen glycerol stocks used, considering the fact 
that P450 expression was successful in the first trial. On the other hand, when the 
expression procedure was followed by SDS electrophoresis (Figure 3.3.10), a band with a 
molecular weight characteristic of the truncated CYP2D6 is present in whole cells (too 
dilute), clarified lysate (supernatant), Ni
2+
 -bound and the flow through (FT) fraction. The 
pellet obtained after clarification of the cells lysate does not have the CYP2D6 band, as 
expected. When the expression was performed using freshly transformed BL21 cells 
grown in 2.5 L flasks containing a maximum of 500 mL of TB media (to allow efficient 
aeration), the cell lysate exhibited a Soret band around 400 nm and a shoulder at ~ 423 
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nm (Figure 3.3.11, trace A). The reduced CO difference spectrum shows a maximum at 
443 nm, which is ~ 5 nm lower than the expected (Figure 3.3.11, trace B-A). 
Surprisingly, when the cell lysate was treated with 1 L of freshly prepared 12 mg/mL 
Na2S2O4, a feature at ~ 447 nm appears after 10 minutes even before adding CO (Figure 
3.3.12), possibly indicating a ferrous hexacoordinated heme. Moreover this shoulder at 
447 nm diminishes with bubbling of CO. It was also noted that the pCWori+ vector 
utilized in the subcloning of the truncated CYP2D6 was shown (sequencing performed by 
Gensript) to exhibit a deletion beyond the XbaI site (see Figure 3.2.2), which was initially 
assumed to be by design (by Ortiz de Montellano, when they constructed the P450cam 
expression plasmid)
140
 and hence inconsequential to expression of functional protein. 
However the present results may be indicating the effect of the deletion on the 
expression, possibly resulting in an incorrectly folded protein. Obviously, it seems 
possible that subcloning of the truncated gene of CYP2D6 into a functional pCWori+ 
expression vector might result in the production of functional soluble protein. Recently, 
Pan, Y. et al
141
 have designed an expression system for the full length CYP2D6 with the 
N-terminus modified to incorporate eight residues from bovine CYP17. They 
demonstrated successful expression of CYP2D6 by immunoblotting and reduced CO 
difference spectral scanning, obtaining holoprotein yields of 371 pmol/mg protein. 
Noting that solubilization of the full length protein may require utilization of detergents; 
this expressed protein may be more effectively solubilized with the nanodisc technology 
elegantly developed by the Sligar group,
142–144
 in which an encircling amphipathic 
membrane scaffold protein (MSP) capable of stabilizing a phospholipid bilayer functions 
as a belt around a hydrophobic core. The advantage of this technology is that the protein 
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is essentially in a native like environment, permitting better characterization by 
biophysical methods.  
 
Figure 3.3.7 The absorption spectra of clarified cell lysate containing crude CYP2D6 
(red trace) and the ferrous CO difference spectra of CYP2D6 
 
 
 
 
Figure 3.3.8 The absorption spectra of crude CYP2D6 (top trace), Ni
2+
 -NTA bound 
fraction (middle trace) and the Ni
2+
 flow through fraction (bottom trace). The insert 
(right) shows the full spectrum of the eluted bound fraction of CYP2D6 
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Figure 3.3.9 The absorption spectrum of the total cell lysate (from subsequent CYP2D6 
expression trials) saturated with CO and incubated in excess sodium diothionite 
 
 
Figure 3.3.10 SDS-PAGE monitoring CYP2D6 expression and purification (bands 
in the black rectangular box are possibly from the truncated CYP2D6).  Lane 1 
(marker), 2 (whole cells), 3 (cell pellet after lysis), 4 (cytosolic fraction), 5 (Ni-
NTA column flow through fraction), 6 (Ni-NTA bound fraction), 7 (CYP2D6 from 
Prof. Waskell). 
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Figure 3.3.11 The UV-vis absorption spectra of CYP2D6 lysate (A), its Na2S2O4 reduced 
CO form (B) and the difference spectrum of B-A 
 
 
 
Figure 3.3.12 The absorption spectra of CYP2D6 cell lysate (A), Na2SO4 reduced forms 
(B), reduced CO forms (C) and the difference spectra of B-A and C-A 
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Figure 3.3.13 Part of the pCWori+ sequence in the multiple cloning site region, the 
highlighted part shows the deleted bases in the P450cam construct used for subcloning 
the CYP2D6 gene 
 
 
3.3.3 Resonance Raman Spectroscopy of [5-13C] -ALA P450cam 
 
The high frequency resonance Raman spectra of the natural abundance and 
[5-
13
C] -ALA SBP450cam are shown in Figure 3.3.14. The oxidation state marker band, 
4 for the natural abundance P450cam shown in the top trace (A) occurs around 
1370 cm
-1
 as expected for the ferric form of the protein, the mode is shifted by 13 cm
-1
 
for the isotopically enriched analogue (trace B). This is to be expected in as much as this 
A1g porphyrin breathing mode contains significant contributions from the C−N 
stretches
42–44
 four of which are 
13
C enriched (Figure 3.3.14 insert). Another mode of 
interest, which shifts significantly upon isotopic substitution, is the so called spin state 
marker band or 3, and has been previously shown to arise from C− Cm symmetrical 
stretches.
42
 The other spin state marker band, 2 occurring at 1570 cm
-1
 for the natural 
abundance and contains substantial contributions from the (C− C) stretching mode 
only shifts slightly and appears as a broad band centered at 1568 cm
-1
. Normal mode 
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calculations and isotopic studies of heme model compounds demonstrated mixing of the 
C – C and C – Cm stretching modes although less significant for 2,
42–45
 it may explain 
the broadening observed in the present work. Interestingly, 
13
C isotopic substitution 
reveals the two vinyl stretching modes, which have been previously identified in 
P450cam reconstituted with protoheme-d4.
22
  
The corresponding low frequency RR spectra shows further evidence of isotopic 
substitution particularly with the mode containing significant contributions from 
symmetric pyrrole deformation (7) shifting down with 13 cm
-1
.
42
 Additionally, a new 
feature at 412 cm
-1
, presumably arising from a vinyl bending mode, is activated in the 
13
C 
enriched analogue of P450cam (Figure 3.3.15).  These observations provide RR 
spectroscopic evidence for the successful heterologous expression of the bacterial 
P450cam bearing 
13
C enriched prosthetic group at the Cand Cm positions.  
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Figure 3.3.14 The high frequency RR spectra of the natural abundance (A) and [5-
13
C] -
ALA (B) substrate bound P450cam acquired with the 406 nm laser excitation line at 
room temperature. Insert: heme numbering, the 
13
C enriched carbons are marked with 
black dots 
 
 
Figure 3.3.15 The low frequency RR spectra of (A) and [5-
13
C] ALA (B) substrate bound 
P450cam acquired with 406 nm laser excitation 
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3.3.4 NMR spectroscopy of [5-13C] -ALA P450cam 
 
 
(a) Initial attempts 
 
NMR measurements were acquired for both the high (HS) and low spin (LS) 
forms of natural abundance P450cam and its 
13
C-labeled analogue. Specifically, 1D 
13
C, 
1
H and 2D 
1
H-
13
C HSQC NMR experiments were performed to identify the meso proton 
resonances, which are, in this case, required in NOE measurements. The inherent long 
electronic spin relaxation time of the heme iron causes very short relaxation times of the 
surrounding protons resulting in large line widths of the paramagnetically shifted 
resonances (Figure 3.3.16). The four hyperfine-shifted signals (A-D in Figure 3.3.16) 
outside of the protein envelope have been assigned to the heme peripheral methyl 
substituents.
72,73,145
 Narrow line widths permits utilization of NMR NOE experiments in 
deriving distances between points of interest; therefore it is essential to obtain good 
quality 1D spectra, which is facilitated by using as highly concentrated protein solutions 
as is possible. Slightly reduced line widths are realized in the LS form of the protein, 
which is obtained by removal of the bound camphor, however as shown in the trace II of 
Figure 3.3.16, the spin state conversion from HS to LS is not 100%.  This may be due to 
incomplete removal of the substrate (camphor) following passage of the camphor bound 
P450cam through Sephadex G25 column equilibrated with MOPS buffer. The optical 
absorption spectra however showed the characteristic 417 nm band of the camphor-free 
P450cam (SFP450cam). This was also observed for the 5-
13
C-ALA SFP450cam as shown 
in Figure 3.3.16 (trace III); the percentage of the LS form of P450cam may be increased 
by passing the protein through the column (equilibrated with MOPS buffer) a couple of 
times before exchanging the buffer prior to collecting NMR data. In the 1D proton NMR 
spectra the meso protons resonances are not easily identifiable even in the low spin form. 
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They have been reported for P450cam to be possibly in the -20 and -40 ppm upfield 
region.
72
 Fortunately,
 13
C enrichment at the four methine positions permits utilization of 
13
C-filtered NMR methods, which can facilitate the identification of the meso protons. 
However, the 2D NMR (HSQC) for the labeled SBP450cam (Figure 3.3.17 bottom trace), 
indicates no major differences from the native SBP450cam spectrum and no detectable 
meso resonances. The minor differences observed were later discovered to be due to the 
formation of the inactive form of the enzyme (Figure 3.3.18). This is possibly due to the 
long NMR acquisition times at room temperature, especially for the substrate free forms 
of the enzyme, which gave similar results. 
  
(b) Improved methods 
 
The utilization of a strong ligand field ligand, such as cyanide, to induce LS 
formation, is advantageous, noting that substrate-free LS forms, obtained by removing of 
the camphor substrate, are unstable and will likely convert to the P420 form during long 
NMR data collection. NMR studies on the cyanide complex of SBP450cam have been 
reported previously.
73
 The low spin heme results in significantly reduced line widths, 
which may augment NOE sensitivity. In addition, the stability of the cyanide complex of 
SBP450cam permit for the acquisition of NMR data at elevated temperatures.
72
 In order 
to improve the sensitivity of the NMR methods applied in this work, samples of the 
cyanide complex of both the natural abundance and 
13
C enriched SBP450cam were 
employed (vide infra).    
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Figure 3.3.16 The 1D 
1
H NMR of the natural abundance SBP450cam (I), natural 
abundance SFP450cam (II) and 5-
13
C-ALA SFP450cam (III); the heme methyl 
resonances are denoted A-D 
 
 
 
 
Figure 3.3.17 The 1D version of 
1
H-
13
C HSQC spectra of the natural abundance (top 
trace) and 
13
C enriched (bottom trace) substrate-bound P450cam; sample concentration 
was ~0.2 mM in 30 mM deuterated phosphate buffer 
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Figure 3.3.18  The absorption spectrum of [5-
13
C] SBP450cam after collection of 1 D 
1
H-
13
C HSQC data 
 
 
Cyanoferricytochrome P450cam NMR 
 
 
The NMR samples (natural abundance and 
13
C labeled) used in the experiments 
described below contained ~ 0.4-1 mM P450cam in 30 mM phosphate D2O buffer, pH 
7.4, 100 mM KCl, 10 mM KCN. The formation of the low spin substrate bound 
cyanoferricytochrome P450cam was verified by absorption spectroscopy (Figure 3.3.19) 
and is in agreement with the previously reported spectrum of the cyanide complex of 
microsomal P450.
146
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Figure 3.3.19 The absorption spectra high spin ferric substrate-bound P450cam (red 
trace) and its cyanide complex (black trace) 
 
 
3.3.4.1 1D 1H NMR 
   
 
Proton NMR experiments were performed at 25 °C, for the cyanide complex of 
the natural abundance and 
13
C-enriched substrate-bound P450cam, using a standard pulse 
sequence (Figure 3.3.20). The hyperfine shifted signals occurring at  21.8 and 11.3 ppm 
(black trace in Figure 3.3.20) have been assigned previously to the 8- and 3-methyl 
peripheral groups, respectively.
73
 The 1D 
1
H spectrum of the 
13
C enriched cyanide 
complex of SBP450cam (red trace) is essentially identical to the natural abundance (black 
trace), as expected. However, due to the fast relaxation of protons in the paramagnetic 
environment, the methine proton resonances are still not detectable, even at elevated 
temperatures (40 °C), where only slight shifts are observed (blue trace). The 1D spectrum 
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was collected before and after multidimensional experiments (vide infra) to ensure 
sample integrity. 
 
 
 
Figure 3.3.20 The 1D 
1
H NMR spectra of the natural abundance (black) and 
13
C enriched 
cyanide complex of P450cam at 20 °C (red) and 40 °C (blue) 
 
 
3.3.4.2 13C NMR 
 
 
In order to determine the methine proton signals using a 2 D experiment 
(HSQC/HMQC), a 1D 
13
C NMR was performed at 20 °C for both the natural abundance 
and 
13
C enriched cyanide complex of SBP450cam (black and red traces in Figure 3.3.21). 
The large line width arises from the very short relaxation time of the heme protons as 
mentioned above. The carbon signals A-H (red trace), which are clearly absent from the 
124 
 
 
natural abundance spectrum (black trace), were reasonably attributed to the 
13
C enriched 
methine and Ccarbons of the heme consistent with the number of 
13
C labeled carbons 
(red trace of Figure 3.3.21). Performing the experiment at 40 °C, for the 
13
C-enriched 
SBP450cam, results in slight shifts to resonances A-E and attenuation of signals F, G and 
H and appearance of a new (N) feature around 56 ppm (blue trace). This may be due to 
the changes in longitudinal relaxation of the heme resonances at 40 °C.  
 
 
Figure 3.3.21 The 
13
C NMR of the natural abundance (black trace) and 
13
C enriched (top 
traces; red: 20 °C, blue: 40 °C) cyanide complex of P450cam. Insert shows the positions 
of 
13
C enrichment (black dots) 
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3.3.4.3 2D HMQC 
 
Figure 3.3.22 shows the 2D HMQC spectra of the 
13
C enriched cyanide complex 
of SBP450cam collected at 25 °C (red trace) and 40 °C (blue trace) with a recycle delay 
of 10 ms and decoupling turned off. Protons giving rise to the signals labeled A-D are 
reasonably assigned to the methine positions in as much as the corresponding 
13
C 
chemical shifts (A-D) are consistent with those observed in the 1D 
13
C NMR experiment 
for the labeled cyanide complex of SBP450cam (Figure 3.3.21). Interestingly, the 
methine proton signals occur in the diamagnetic region making their identification 
without selective 
13
C enrichment virtually impossible as noted in the 1D NMR 
experiment above. This observation has been reported earlier in a similarly 
13
C enriched 
heme cofactor of Hydrogenobacter thermophilus cytochrome c552.
80
 The four cross peaks 
are clearly absent from the 2D HMQC spectrum of the natural abundance cyanide 
complex of SBP450cam (Figure 3.3.23) further confirming their assignment to the 
13
C 
enriched methine positions, however specific assignments (, ,  and ) is not possible 
at this point. In the Hydrogenobacter thermophilus cytochrome c552, specific assignments 
was achieved using 
1
H-
1
H NOESY cross-peaks between the heme methyl and meso 
proton resonances.
80
 Without decoupling, one will expect to observe doublets in the 
methine position cross peaks, however as noted above, the relatively fast relaxation, as 
evident from the large line widths exhibited in the 
13
C NMR experiment, renders this 
spectral resolution impossible. In addition, no 
13
C-
13
C coupling was observed in the 1D 
13
C spectrum due to the inherent fast relaxation of these resonances. Also, noting that one 
of the meso carbons ( position) is not attached to a 13C enriched pyrrole -carbon, one 
would expect only 
1
H-
13
H coupling in contrast to the other 3 meso positions, which will 
exhibit coupling from both the attached proton and labeled pyrrole -carbon. This 
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unique, meso  carbon has been exploited in the assignment of the meso resonances by 
NOE methods in similarly
75,147
 
13
C enriched heme oxygenases. However, probably due to 
fast relaxation, these couplings were not observed in the current work. The 2D HMQC 
spectra (obtained at 35 °C) of the cyanide complex of the heme oxygenase from 
Coryne-bacterium diphtheria (cd-OH) that has been reconstituted with a heme group 
13
C-labeled at the C and Cm positions exhibited four correlations at {58.58, -2.58}, 
{33.27, 2.42}, {21.73, 7.78} and {18.75, 8.19} assigned to meso-, ,  and  positions 
respectively.
147
 In the current work a similar pattern was observed in the HMQC 
experiment (Figure 3.3.22) performed at 40 °C with crosspeaks appearing {84.7, 2.1}, 
{77.6, 4.7}, {46.9, 8.3} and {40.6, 10.8}, however, with the resonances downshifted, 
probably due to differences in the effect of the unpaired electron and active site 
structures.  
127 
 
 
 
 
Figure 3.3.22 The 2 D HMQC spectra for the 
13
C enriched cyanide complex of 
SBP450cam collected at 25 °C (red) and 40 °C (blue).  
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Figure 3.3.23 The 2D HMQC spectra of the natural abundance cyanide complex of 
SBP450cam collected overnight at 25 °C 
 
 
3.3.4.4 1H-1H NOESY 
 
 
1
H-
1
H NOESY-HMQC data was collected with 100 ms pre-saturation delay and 
10 ms mixing time. However, possibly due to low sensitivity, only two of the presumably 
meso protons are detectable (Figure 3.3.24). The signal at 8.3 ppm exhibits 2 cross-peaks 
at ~ 4.01 and 1.37 ppm, which are located in the proton resonances envelope. The 
resonance at 4.01 ppm may be arising from the meso proton signal observed in the 
HMQC spectra (red cross-peak B in Figure 3.3.22), however this signal shifts to 4.7 ppm 
at 40 °C. Assignment of the signal at 1.37 ppm, is impossible at this point, since it may be 
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arising either from the protein side chain residues or the substrate camphor. However, 
detection of the corresponding signal at 1.37 ppm in the 1D 
1
H spectra of the 
13
C-
enriched cyanide complex of SBP450cam is impossible due to the overwhelming protein 
signals. The signal might be buried in the protein envelope, making it impossible to 
detect, unless it was attached to a 
13
C-enriched carbon, where detection might be possible 
using a double-filtered NOE. Interestingly, the 
1
H NMR spectrum of KPi buffer 
containing free camphor exhibits a peak at 1.37 ppm arising from the 5 endo position of 
the substrate camphor (Figure 3.3.25). According to the crystal structure of the cyanide 
complex of P450cam, the 5 endo position is about 3.85 Å from the heme  position; thus, 
the NOE at 1.37 ppm might possibly be arising from the 5 endo proton of camphor. 
Assignment of this resonance can be confirmed by loss of NOE upon utilization of 
perdueterated camphor or its substrate analogues, such as adamantanone. It is important 
to note that the NOE sensitivity might be improved by optimizing the mixing time and 
relaxation delay, this may lead to observation of additional crosspeaks, ideally from 
substrate protons. This will possibly lead to the derivation of distances between the heme 
reference points and substrate protons providing preliminary data on the disposition of 
the substrate in the active site pocket.  
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Figure 3.3.24 
1
H-
1
H NOSEY-HMQC spectrum of 
13
C-enriched cyanide complex of 
SBP450cam at 40 °C 
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Figure 3.3.25 1D 
1
H NMR of the 
13
C-enriched cyanide complex of SBP450cam at 40 °C, 
with part of the diamagnetic region expanded (bottom trace) and KPi buffer containing 
10 mM camphor (top trace)  
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3.4 Summary 
 
 
The specific aim of this work was to exploit NMR spectroscopy in deriving 
experimental parameters for application in docking routines, which are commonly 
employed in defining relative binding affinities in drug metabolism P450s. To this end, 
an HU227 strain of E.coli, that lacks the -ALA synthase gene, was utilized in the 
expression of P450cam harboring a prosthetic group labeled with 
13
C at the Cm and C 
positions by supplementing the bacterial growth media with [5-
13
C] -ALA. The heme 
precursor was successfully synthesized in four steps from [2-
13
C] glycine, giving yields 
of up to 70%. Successful incorporation of 
13
C at the Cm and C positions was confirmed 
by RR of the ferric form of SBP450cam. Significant perturbations of the oxidation and 
spin state marker bands (in the high-frequency region) due to isotopic substitution were 
observed. In the low-frequency RR, 7 downshifts with about 13 cm
-1
 upon isotopic 
substitution. Additionally, activation of a vinyl bending mode at 412 cm
-1
 in the low-
frequency RR spectra of the 
13
C-enriched SBP450cam was observed, further confirming 
successful expression of isotopically labeled P450cam.  
In an effort to heterologously express a 
13
C-enriched CYP2D6, a truncated 
CYP2D6 gene was designed and commercially synthesized. The gene delivered in a 
pUC57 expression vector and transformed into E.coli cells, was shown to express P450 
by reduced CO difference spectra of the total cell lysate. However, subcloning the gene 
into the pCWori expression vector, which is normally used for P450 expression, did not 
result in production of P450 as judged from the reduced CO difference spectra of total 
cell lysate. In fact, a species chacteristic of a hexacoordinated heme was observed; this 
was possibly due to the deletion in the pCWori sequence used for subcloning. Subcloning 
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of the truncated gene of CYP2D6 into a functional pCWori+ expression vector might 
possibly result in the production of functional soluble protein. 
The 
13
C-enriched P450cam was employed in a ‘proof of principle’ exercise for the 
strategy of defining active site structure in mammalian cytochromes P450 using NMR 
methods to furnish necessary experimental restrictions in docking routines. Identification 
of the meso protons was achieved by employing 1D 
13
C and HMQC experiments. The 
HMQC spectra of cyanide complex of 
13
C-enriched SBP450cam exhibited four cross-
peaks [{46.9, 8.3}, {40.6, 10.8}, {77.6, 4.7}, {84.7, 2.1}], the proton signals lie in the 
diamagnetic region, making detection impossible without selective 
13
C-enrichment. 
1
H-
1
H-HMQC showed that, the signal at 8.3 ppm is within NOE distance to two resonances 
at 1.37 and 4.01 ppm. However, assignment of these signals is impossible at this point, as 
they are buried in the protein envelope, although the signal at 4.01 ppm might possibly be 
coming from the heme meso proton, observed in the HMQC experiment performed at 25 
°C. On the other hand the signal at 1.37 ppm corresponds to the 5 endo proton of 
camphor, which is about 3.85 Å from the heme position, suggesting that the observed 
NOE might be arising from the substrate. Utilization of perdeuterated camphor or its 
substrate analogues (e.g. adamantanone) and concomitant loss of NOE to the 1.37 ppm 
signal, will confirm its assignment to the 5 endo position. The sensitivity of the NOE 
experiments could be improved by utilizing highly concentrated samples and exploiting 
high field instruments such as the 900 MHz equipped with a cryoprobe. In addition, 
expression of a fully deuterated proton will aid in the identification of NOEs only 
between heme reference points and substrate or inhibitors. This will possibly lead to the 
determination of relative distances between methine protons and substrate proton 
resonances in the solution phase. It will be interesting to compare distances derived in the 
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solution phase with those calculated from the corresponding crystal structure. Inasmuch 
as there are still additional experiments to be done, the observation of NOEs from the 
heme reference points in this ‘proof of principle’ exercise project, provides an 
encouraging step in the direction of utilizing NMR methods in defining the active site 
structure.   
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